Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

Olga M. Kutova 1, Evgenii L. Guryev 1, Evgeniya A. Sokolova 1, Razan Alzeibak 1 and Irina V. Balalaeva 1,2,*

1 The Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, 23 Gagarin ave., Nizhny Novgorod 603950, Russia; kutovaom@gmail.com (O.M.K.); eguryev@ibbm.unn.ru (E.L.G.); malehanova@mail.ru (E.A.S.); razanzybak@gmail.com (R.A.)
2 The Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University, 8-2 Trubetskaya str., Moscow 119991, Russia
* Correspondence: irin-b@mail.ru; Tel.: +7-831-4623-205

Received: 26 November 2018; Accepted: 7 January 2019; Published: 10 January 2019

Abstract: Malignant tumors are characterized by structural and molecular peculiarities providing a possibility to directionally deliver antitumor drugs with minimal impact on healthy tissues and reduced side effects. Newly formed blood vessels in malignant lesions exhibit chaotic growth, disordered structure, irregular shape and diameter, protrusions, and blind ends, resulting in immature vasculature; the newly formed lymphatic vessels also have aberrant structure. Structural features of the tumor vasculature determine relatively easy penetration of large molecules as well as nanometer-sized particles through a blood–tissue barrier and their accumulation in a tumor tissue. Also, malignant cells have altered molecular profile due to significant changes in tumor cell metabolism at every level from the genome to metabolome. Recently, the tumor interaction with cells of immune system becomes the focus of particular attention, that among others findings resulted in extensive study of cells with preferential tropism to tumor. In this review we summarize the information on the diversity of currently existing approaches to targeted drug delivery to tumor, including (i) passive targeting based on the specific features of tumor vasculature, (ii) active targeting which implies a specific binding of the antitumor agent with its molecular target, and (iii) cell-mediated tumor targeting.

Keywords: targeted drug delivery; cancer treatment; EPR-effect; passive targeting; cancer-specific molecular targets; active targeting; cell-mediated targeting

1. Introduction

A personalized approach has emerged a few decades ago as a rapidly developing paradigm of disease treatment. The shift to personalized medicine is most clearly represented in oncology: according to the Personalized Medicine Coalition (PMC) reports 2014–2017 approximately 50% of lately FDA approved novel personalized medicines are antitumor agents. The progress of the approach is based on accumulation of large amount of data on the molecular basis of carcinogenesis and tumor growth regulation as well as architectural peculiarities of tumors tissue [1]. Structural and molecular features of tumors provide an ability to directionally deliver antitumor drugs with minimal impact on healthy tissues and reduced side effects. The overall strategy of personalized treatment implies histological analysis and molecular profiling of an individual tumor, potential targets characterization and selection of a personal treatment tactics. The additional testing on patient-derived 3D-in vitro or in vivo tumor models can be included to experimentally confirm the potency of the chosen drug or drugs combination [2–4].
Among the features which characterize neoplastic lesions are disordered (compared to normal) tissue structure and aberrant vasculature mostly due to a discrepancy in the tumor mass growth rate and the rate of formation of new blood and lymphatic vessels. This causes the tumor cells deprivation in nutrient and oxygen and elevation of tumor interstitial pressure. Hence hypoxic and acidic conditions develop in the tumor tissue and the extracellular matrix undergoes a transformation towards compaction/stiffness which promotes further tumor progression [5–7]. These alterations in tissue architectonics, microenvironment and vasculature become the selective criteria which distinguish the normal and malignant tissues, and thus they can be used as a basis for rational drug design and targeted delivery to tumor site.

Tumor targeting effectiveness can be enhanced by taking into account an altered molecular profile of malignant cells. Tumors are capable of a massive production of molecular factors which condition tumor progression and invasion (growth factors, interleukins, proteases of different classes, etc.) and are characterized by overexpression of G-protein-coupled receptors and receptors of growth factors, transferrin, some interleukins, vitamins, and sugar moieties. The presence of the characteristic molecules on the tumor cells surface and in tumor microenvironment can serve as a specific label to targeted drugs functionalized with specific targeting moiety, leading to increased drug accumulation in the tumor [8–10].

An alternative relatively new approach is based on using cells which possess a tropism to tumors as carriers for a therapeutic agent. The loaded cells can migrate along with the gradients of molecules acting as attractants e.g., cytokines, chemokines or growth factors. The promising candidates for cell-based drug delivery are immunocytes. The main benefits of this approach are drug delivery through blood–tissue barriers, hiding the agent from the cells which are responsible for drug clearance and metabolizing; and prolonged circulation in an organism [11].

It should be noted that the targeted treatment implies also using a wide range of agents that do not exhibit a specific tropism to tumor cells, but have a specific action towards them. In particular, tyrosine kinase inhibitors can be attributed to this group. In the present work we do not consider this type of agents.

In this review we summarize the information on the diversity of currently existing approaches to targeted drug delivery to tumor, including (i) passive targeting based on the specific features of tumor vasculature, (ii) active targeting which implies a specific binding of the antitumor agent with its molecular target, and (iii) cell-mediated tumor targeting.

2. Passive Targeting

2.1. Tumor Vasculature Peculiarities

Passive targeting is associated with the structural features of the tumor vasculature (Figure 1). The formation of new vessels that provide tumor nutrition and metabolite outflow is a vital condition for tumor development. This process starts when the tumor reaches about 1–2 mm in size [12–14]. The aggressive growth of malignant cell population is accompanied by a massive release of pro-angiogenic factors, which leads to the chaotic growth of newly formed vessels. The tumor vascular bed is comprised of immature and tortuous vessels and is characterized by a disordered structure with no defined vessel hierarchy and no clearly distinguishable arterioles, capillaries, and venules [15]. Tumor vessels are irregular in shape and diameter; they possess uneven inner surface with abnormal protrusions, blind ends, arteriovenous shunts, and so-called plasma channels that lack blood cells [16,17].

The newly formed lymphatic vessels also have aberrant structure: they are dilated and their endothelial lining is discontinuous and leaky. The integrity of tumor lymphatic vessels is often more disrupted than that of blood vessels. This might be due to better mechanical resistance of blood vessels to the excessive interstitial pressure of the tumor, conditioned by a residual arterial pressure [18,19]. Lymphatic vessels play an important role in tumor progression and metastasis. Although intratumoral
lymphatic network is nearly absent, solid tumors tend to develop an extensive surrounding network of lymphatic vessels. As the tumor mass is poorly drained, an excessive interstitial pressure induces a backflow of exfoliated tumor cells up to the lymph nodes, causing distant metastases, which are associated with poor prognosis [20].

It is also important to mention that advanced tumors often form vessel-like structures lined by tumor cells, in order to overcome severe hypoxia and nutrient deprivation. This phenomenon is known as vasculogenic mimicry and it is associated with poor prognosis and low survival rates [21,22].

**Figure 1.** Scheme illustrating the principle of passive drug delivery to the tumor. EPR effect: Permeability and Retention effect; UCNP: upconversion nanoparticles. The extravasation and penetration of nanoscale agents into the tumor is due to the disordered structure of the tumor vessels, their discontinuous endothelial lining and the disrupted integrity of the basement membrane. Irregular diameter and leakage of the walls of the newly formed lymphatic vessels impede the outflow of fluid and the removal of nano-sized agents from the tumor. Insets I and II indicate examples of passive drug delivery in vivo. I—Polymer particles based on water-soluble polymer brushes (polyimide-graft-poly(methacrylic acid)) are used to deliver photodynamic dye (tetra(4-fluorophenyl)tetracyanoporphyrine). The image was obtained by whole-body imaging 24 h after intravenous injection of a dye to BALB/c mouse with CT26 allograft (murine colorectal carcinoma) in the left thigh. The position of the tumor is indicated by an arrow. The fluorescence intensity of the dye is presented in the gradient red to yellow scale, where yellow corresponds to the maximum signal. II—Passive delivery of upconversion nanoparticles (UCNP) of composition, NaYb:Tm:F4/NaYF4 covered with alternating copolymer of maleic anhydride and 1-octadecene (PMAO). Tumor and muscle tissue images were obtained ex vivo by confocal fluorescence microscopy 3 h after intravenous injection of UCNP-PMAO to a BALB/c mouse with SK-BR-3 xenograft (human breast adenocarcinoma). Purple signal corresponds to the UCNP photoluminescence. Scale bar 20 µm.
It is also important to mention that advanced tumors often form vessel-like structures lined by tumor cells, in order to overcome severe hypoxia and nutrient deprivation. This phenomenon is known as vasculogenic mimicry and it is associated with poor prognosis and low survival rates [21,22].

The vascular network architectonics and geometric resistance to blood flow determine significantly impaired functionality of the tumor vasculature: the decreased blood flow rate, inadequate oxygen supply and subsequently the development of hypoxia at the micro-regional level [23–26]. The discontinuous endothelial lining of tumor vessels with the lack of smooth muscle layer and impaired integrity of the basement membrane conditions an increased vascular permeability which leads to the release of vascular contents into the intercellular space and to an elevation of interstitial pressure in the tumor, which in turn provokes a collapse of the vessels and insufficient perfusion of the tumor [27,28].

The gaps between endotheliocytes and fenestrations in tumor vessels can vary in diameter from 200 nm to 2 µm and more [29,30], whereas in most normal tissues they do not exceed 5 nm [31].

In addition to the inconsistency between the rates of tumor mass increase and vascular growth there are a number of factors which are involved in vascular permeability regulation in tumors. Among them are the kinin-kallikrein system [32,33], nitric oxide NO [34,35], reactive oxygen and nitrogen species, including H2O2, O2•-, ONOO-, formed in various reactions both by tumor cells and tumor infiltrating leukocytes [36,37], carbon monoxide CO, which is a product of the reaction of hemoxygenase [38], prostaglandins [39], matrix metalloproteinases [40,41], protein factors, including vascular endothelial growth factor (VEGF), transforming growth factor TGF-β, tumor necrosis factor TNF-α [42–44]. The tumor development and tumor-associated inflammation typically shift the balance of the listed systems towards an increase in vascular permeability, which is a factor contributing to the invasation and dissemination of tumor cells.

2.2. EPR-Effect in Drug Delivery to Tumor

Both structural and functional features of the tumor vasculature determine the relatively easy penetration of large molecules, supramolecular complexes, as well as any nanometer-sized particles independently of their nature, through the blood–tissue barrier and their accumulation in the tumor tissue. This phenomenon was first described by Y. Matsumura and H.A. Maeda and called the Enhanced Permeability and Retention effect (EPR effect) [45]. The idea of using dimensional effects for selective delivery caused a wide response in the research community (see reviews: [46–51]).

To date, the EPR effect has been shown for a wide range of agents e.g., liposomes, micelles, nanodisperse albumin and its modifications, polymer nanoparticles, dendrimers, inorganic nanoparticles of different composition. Some of these agents such as liposomes, micelles, and nanodisperse albumin modifications are approved for clinical practice or undergo different phases of clinical trials, other types of agents are being intensively investigated. A brief overview of them is given below.

Liposomes are the nanoscale vesicles composed mainly of phospho- and sphingolipid molecules which are organized into a bilayer and enclosed into a ball-like structure. To date liposomal anticancer drugs approved by FDA are represented by liposomal forms of doxorubicin (Doxil® (ALZA corp., Mountain View, CA, USA), Caelyx® (Janssen Inc., Toronto, Canada), Myocet® (Teva B.V., Haarlem, The Netherlands)) used for treatment of ovarian and breast cancer, multiple myeloma and Kaposi’s sarcoma [52,53], daunorubicin (DaunoXome® (Galen Ltd., Craigavon, UK)) for treatment of HIV-associated Kaposi’s sarcoma [54], cytarabine (Depocyt® (Pacira Pharmaceuticals, Inc., San Diego, CA, USA)) for treatment of neoplastic meningitis, mifamurtide (Mepact® (Takeda Pharmaceutical Co. Ltd., Tokyo, Japan)) for treatment of high-grade, resectable, non-metastatic osteosarcoma, vincristine (Marqibo® (Spectrum Pharmaceuticals, Inc., Henderson, NV, USA)) for treatment of acute lymphoblastic leukemia and irinotecan (Onivyde® (Merck Millipore Pharmaceuticals, Inc., Cambridge, MA, USA)) for treatment of metastatic pancreatic adenocarcinoma. Clinical trials are carried out on liposomal forms of doxorubicin and its analogues, cisplatin, topoisomerase I (topotecan, lurtotecan...
and irinotecan metabolite) and II (mitoxantrone) inhibitors, taxanes (paclitaxel and docetaxel), siRNAs, and others. A comprehensive review on liposomal antitumor formulations is provided elsewhere [55,56]. The further directions in antitumor liposomal formulations progress are the development and improvement of stimuli-sensitive smart liposomes (thermo-, redox-, ultrasound-, enzyme-sensitive), magnetic liposomes, and liposomes for photodynamic therapy [57–63].

A promising nanoscale drug carrier is the nanodisperse albumin. This protein possesses an outstanding binding capacity due to its molecular structure [64]. Thus it is possible to modify the properties of albumin-based nanoparticles using surfactants, cationic and thermosensitive polymers, PEG, or targeting moieties such as folate, transferrin, apolipoproteins, peptides, or mAbs. [65]. The positive example of using albumin nanoparticles in antitumor treatment is confirmed by a successful application and FDA approval of Abraxane® (Celegene Corporation, Summit, NJ, USA) (paclitaxel incorporated in albumin nanoparticles for a metastatic breast cancer, non-small cell lung carcinoma, pancreatic cancer, cervical cancer [66–70]. Albumin based nanoparticles loaded with lapatinib (triple negative breast cancer and HER2-positive breast cancer), gemcitabine (pancreatic cancer), siRNAs (breast and lung cancers), gold nanoparticles for NSCLC, photosensitizers are also being developed [71–77].

Organic polymer particles are a promising alternative to liposomes or albumin. An advantage of using such type of particles is in the rational molecule design that allows highly reproducible synthesis of the carriers with desired properties. There is a variety of intensively studied drug carrying vehicles which can be designed with synthetic (polyethylene glycol, polylactic and polyglycolic acids, polycaprolactone, derivatives of polymethacrilic acid, etc.) [78–83] or natural polymers (gelatin, collagen, chitosan, dextran, solid lipid nanoparticles, etc.) [84–87]. Besides the material-based diversity of the polymer nanoparticles, there is also a diversity in shape, size, surface charge and structural organization [88–93].

To combine targeted drug delivery with a possibility to use the agent for diagnostic purposes, the inorganic nanoparticles of different composition can be applied. Thus, noble metals are now widely used to create tumor targeting agents. Golden, silver and platinum nanoparticle delivery systems showed pronounced antitumor efficacy towards in vitro and in vivo tumor models [94–98] and represented themselves as a potent tumor imaging agents [99,100]. Highly fluorescent quantum dots, up-conversion nanoparticles, carbon-based nanoparticles are the promising tool for fluorescence guided drug delivery [101–105]. To engage the magnetic resonance imaging, superparamagnetic nanoparticles of iron oxides can be employed [106–109]. Porous inorganic materials are also being developed as containers for therapeutic or imaging compounds [102,110–112]. The above list of organic and inorganic nanoparticles is far from complete and the range of nanoparticles used for the drug delivery is constantly expanding.

As mentioned above passively targeted agents accumulate in the tumor tissue due to its peculiar structure and architectonics. In this respect a fact must be mentioned that nanoscale agents can also be accumulated by tumor associated macrophages which act in this case as a reservoir, gradually releasing the active substance, which significantly prolongs the presence of the agent in the tumor [113].

2.3. Questioning the EPR Efficiency

Despite the generally accepted approach of using the EPR effect for targeted delivery to a tumor, it is worth noting, however, that this effect is well manifested in rapidly growing experimental tumors in animals and cannot be considered common for all solid tumors by default. For example, a meta-analysis of preclinical data collected over 10 years showed that the median value of the drug dose delivered to a tumor when using nanoscale carriers is only 0.7% of that was administered [114]. This value several times exceeds the delivery efficiency of low-molecular analogs, which, as a rule, is no more than 0.2%, but nevertheless cannot be considered as fully satisfying the requirements of clinical oncologists.
Though the multiple reports about successful EPR effect-based creative solutions in cancer treatment are expanding it should be noted, that data are accumulated on the absence of the expected effect when moving from animal models to human tumors [115,116]. The most evident example illustrating the gap between preclinical models and clinical practice is the clinical trials results for FDA-approved nano-formulations Doxil® (PEGilated liposomal doxorubicin) and Abraxane® (nanoparticle albumin-bound (nab)-paclitaxel). The treatment efficiency of Doxil® was comparable to free doxorubicin. Its clinical benefit resulted from the modified profile of side effects, primarily from reduced cardiotoxicity [117]. The second example, Abraxane®, in clinical trials was significantly more efficacious than conventional formulation Taxol. In this case, the emulsion of Cremophor® EL (currently known as Kolliphor® EL (BASF SE, Ludwigshafen, Germany)), a modified castor oil used for paclitaxel solubilization in Taxol, was eliminated, that resulted in significant increase of maximum tolerated dose [118]. In both cases, the benefits over conventional formulations can be credited to EPR-effect only to a small extent.

Currently, the inconsistency in drug distribution in animal tumor models and in tumors of human patients is considered to be a potential cause of such a discrepancy in the results of preclinical and clinical trials. The growth rate of a human tumor and its relative volume is much smaller than in case of an experimental model, at the same time an absolute volume is often much larger. Thus, the microenvironmental conditions in the human tumors have their peculiar characteristics: vascular network with fewer fenestrations, hypoxic and acidified sites formed due to the heterogeneity of the blood supply, heterogeneous basal membrane and reduced pericyte coverage, matrix heterogeneity and rigidity, elevated interstitial fluid pressure which promotes convective transport with subsequent nanomedicine clearance from the central zone of the tumor to its periphery [119,120]. The set of these parameters can vary considerably basing on individual characteristics of the patient, type of the tumor the patient suffers of and the stage of its development, hence the manifestation of EPR effect also differs [121].

Optimization of the carrier size is the simplest and promising approach of improving drugs targeting to tumors, but it demands further development. The following directions seems to be the most applicable: elaboration of the tools for controlled modification of vascular permeability (see review: [50]); systematic study on the dependence between physicochemical properties of the carrier and drug delivery efficiency, which would allow the rational design of agents with desired properties; creation of the personalized treatment approaches with consideration of the histomorphological features of the individual tumor (as an example: [121]); and elaboration of approaches combining the use of the EPR effect with other methods of targeted delivery.

3. Active Targeting

Active targeting is an approach complementary to passive targeting and is aimed at improvement of accumulation selectivity and increased time of intratumoral retention of the antitumor agent. The active targeting strategy implies covalent or non-covalent binding of the antitumor agent to the molecule, which is capable of selective interaction with specific molecules on the surface of target cells (Figure 2). Active targeting of oncological lesions is possible due to altered molecular profile of malignant cells which is resulted from significant changes in tumor cell metabolism (compared to normal cells) at every level from the genome to metabolome [122–124]. We should emphasize that this approach manifests its targeting properties only at microscale: the targeted agent should be located no further than 0.5 nm from the target [125]. The previous drug route from the administration into the body to tumor site is directed by other mechanisms.
The epidermal growth factor receptor family (EGFR, also known as HER1-4) is the most extensively studied in terms of its role in tumor metabolism and as a target for therapy. Overexpression of receptors from this family is characteristic of many types of carcinomas, including breast, lung, stomach, brain, and some other cancers. EGFR/HER1, HER2, and HER3 receptors are commonly targeted for the development of anti-tumor agents through targeted delivery of therapeutic agents. However, only one FDA-approved anti-tumor agent is currently targeted against any member of the EGFR family, excluding non-conjugated therapeutic antibodies. Kadcyla® is an antibody-drug conjugate based on an antibody specific for HER2 (Trastuzumab) and an antimitotic agent called emtansine (DM1), which inhibits the polymerization of microtubules. This agent is used for the second-line treatment of HER2-positive metastatic breast cancer.

**Figure 2.** Scheme illustrating the principle of active drug delivery to the tumor. QD: quantum dots; scFv: single chain fragment variable. Active delivery implies covalent or non-covalent binding of the delivered agent to the moiety, which determines its selective interaction with specific molecules on the surface of target cells. This moiety can be attached directly to the delivered drug or to a nano-sized container loaded with a therapeutic drug. Insets I and II indicate examples of active drug delivery in vivo. I—Active delivery of NIR fluorescent quantum dots (QD) bound with anti-HER2 scFv (4D5scFv). Image of tumor tissue was obtained by confocal fluorescence microscopy 21 h after intravenous injection of QD-4D5scFv to BALB/c nude mice with SK-BR-3 xenograft (human breast adenocarcinoma). The red signal corresponds to QD photoluminescence. Scale bar 10 µm. II—Active delivery of upconversion nanoparticles (UCNP) of NaYb:Tm:F4/NaYF4 composition bound with HER2-specific protein DARPin. The image was obtained by whole-body imaging 2 h after the intravenous (tail vein) injection of the nanocomplex BALB/c mouse with SK-BR-3 xenograft (human breast adenocarcinoma). The position of the tumor is indicated by an arrow. The red signal corresponds to the photoluminescence of the UCNP.

### 3.1. Cancer-Specific Molecular Targets

In order to precisely attack a tumor, an appropriate target should be selected. A target molecule must be overexpressed on the surface of malignant cells compared to normal cells or, in ideal situations, absent in normal tissues (Table 1). Also, the potential use of tumor stroma-associated targets should be noted.
### Table 1. Preclinical and clinical examples of tumor-targeted imaging and drug delivery.

| Target Designation | Targeting Agent | Agent | Patients Group/Animal Model | Reference |
|--------------------|------------------|-------|----------------------------|-----------|
| **EGFR** | Epidermal growth factor receptor | Cetuximab (Erbitux®, Bristol-Myers Squibb Company, New York, NY, USA) | Cetuximab-labeled liposomes loaded with chemotherapy drug Oxaliplatin | Human colorectal cancer xenograft [126] |
| | | Cetuximab conjugated with chemotherapy drug Docetaxel | | Human epidermoid carcinoma (A431) xenograft [127] |
| | | scFv 425 (recombinant immunotoxin 425scFv-ETA) | | Human epidermoid carcinoma (A431) xenograft [128] |
| | | Nanobody 8B6 | | Human epidermoid carcinoma (A431) xenograft [129] |
| | | Nanobody D10 | | Human mammary (MDA-MB-468) and epidermoid (A431) carcinoma xenografts [130] |
| | | EGF fused with toxin gelonin (recombinant targeted toxin EGF/rGel) | | Human epidermoid carcinoma (A431) xenograft [131] |
| **HER2** | Human epidermal growth factor receptor-2 | DARPin (HE)3-G3 | 111In-labeled (HE)3-G3 DARPin for SPECT/CT tumor visualization | Human breast carcinoma (BT-474) xenograft [132] |
| | | Nanobody 2Rs15d | 99mTc-labeled 2Rs15d for SPECT tumor visualization | Human ovarian carcinoma (SKOV-3) xenograft [133] |
| | | scFv 4D5 | Qdot 705 ITK-labeled 4D5scFv for optical tumor visualization (QD-4D5scFv) | Human breast carcinoma (SKBR-3) xenograft [101] |
| | | scFv 4D5 | 4D5scFv fused with Pseudomonas exotoxin A fragment (recombinant immunotoxin 4D5scFv-PE40) | Human ovarian carcinoma (SKOV-kat) xenograft [134,135] |
| | | scFv 4D5 | 4D5scFv fused with toxin gelonin (recombinant immunotoxin rGel/4D5) | Human ovarian carcinoma (SKOV3-V) xenograft [136] |
| | | DARPin9.29 | DARPin9.29 fused with Pseudomonas exotoxin A fragment (targeted toxin DARPin-PE40) | Human breast carcinoma (SKBR-3) xenograft [137] |
| | | Affibody ABY-025 | 111In-labeled ABY-025, 68Ga-labeled ABY-025 | Phase I/II study in patients with breast cancer metastases [138] |
### Table 1. Cont.

| Target | Designation | Targeting Agent | Agent | Patients Group/Animal Model | Reference |
|--------|-------------|-----------------|-------|-----------------------------|-----------|
| DARPin9.29 | $^{90}$Y-dopped upconversion nanoparticles (UCNP) coupled to targeted toxin DARPin-PE40 (UCNP-R-T) | Human breast carcinoma (SKBR-3) xenograft | [139] |
| | | | | | |
| | Trastuzumab (Herceptin®, Genetech, Inc., San Francisco, CA, USA) | Trastuzumab conjugated with cytotoxic agent emtansine (DM1) (Trastuzumab emtansine, or T-DM1) | FDA approved for the treatment of patients with HER2-positive, metastatic breast cancer (Kadcyla®, Genetech, Inc., San Francisco, CA, USA) | [140] |
| HER3 | Human epidermal growth factor receptor-3 | Affibody HEHEHE-z08698-NOTA | $^{68}$Ga-labeled affibody HEHEHE-Z08698-NOTA for PET imaging | Human breast (BT-474) and pancreas (BxPC) carcinoma xenografts | [141] |
| PDGFR β | Platelet-derived growth factor receptor beta | Targeting peptides (PDGF, yITLPPPRPFK) | PDGF-labeled micelles loaded with drug temozolomide (TMZ) | Human glioblastoma (U87) xenograft | [142] |
| IGF-1R | Insulin-like growth factor 1 receptor | Affibody ZIGFR:4551-GGGC | $^{99m}$Tc-ZIGFR:4551-GGGC | Human prostate (Du-145) and breast (MCF-7) carcinoma xenografts | [143] |
| | | mAb IGF-IR | Oxidized single-wall carbon nanohorns with incorporated drug vincristine and wrapped with mAb IGF-IR (VCR@oxSWNHs-PEG-mAb) | Mouse hepatoma (H22) syngraft | [144] |
| Tfr | Transferrin receptor | Transferrin | Transferrin-labeled liposome-DNA for systemic p53 gene therapy (LipT– pSVb) | Human squamous cell carcinoma of the head and neck (JSQ-3) xenograft | [145] |
| PSMA | Prostate-specific membrane antigen | Nanobody JVZ-007 | $^{111}$In-labeled JVZ007 nanobody for SPECT/CT imaging ($^{111}$In-JVZ007-c-myc-his, $^{111}$In-JVZ007-cys) | Human prostate carcinoma (PC-310) xenograft | [146] |
Table 1. Cont.

| Target            | Designation                                                                 | Targeting Agent                                                                 | Agent                        | Patients Group/Animal Model                                                                 | Reference |
|-------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------|------------------------------|------------------------------------------------------------------------------------------------|-----------|
| **Carbohydrate moieties** | Oligosaccharides associated with cell membrane lipids, proteins or peptide glycans | Lectin (Bauhinia purpurea agglutinin, BPA)                                      | BPA-labeled PEGylated liposomes encapsulating drug Doxorubicin (BPA-PEG-LPDOX) | Human prostate carcinoma (Du-145 xenografts)                                                       | [147]     |
| **Mesothelin**    | Mesothelin                                                                  | dsFv SS1                                                                       | SS1dsFv fused with *Pseudomonas* exotoxin A fragment (recombinant immunotoxin SS1(dsFv)PE38) | Phase I study in patients with pleural mesothelioma                                                | [148]     |
| **IL-13Rα2**      | Interleukin 13 receptor α2                                                   | Linear peptide (CGEMGVWRC, or Pep-1)                                           | Pep-1-labeled PEGylated nanoparticles loaded with drug Paclitaxel (Pep-NP-PTX) | Intracranial rat glioma (C6) xenograft                                                          | [149]     |
| **FRα**           | Folate receptor α                                                           | mAb M9346A                                                                    | M9346A mAb conjugated with cytotoxic agent maytansinoid DM4 (Mirvetuximab soravtansine, or IMGN853) | Phase I study in patients with advanced, FRα-positive solid tumors (epithelial serous or endometrioid ovarian cancer, primary peritoneal cancer, fallopian tube cancer, serous or endometrioid endometrial cancer, non-small-cell lung carcinoma, and renal cell cancer) | [150]     |
| **Sugar Carriers**| Membrane carriers of sugars                                                 | Glucose moieties                                                               | D-glucose-labeled fullerene for PDT (C(60)-(Glc3)) | Human triple negative breast cancer (MDA-MB-231) xenograft                                        | [151]     |
| **FSHR**          | Follicle-stimulating hormone receptor                                       | Polypeptide of follicle-stimulating hormone (FSHP)                            | shRNA-loaded FSHP-labeled nanoparticles for blocking growth-regulated oncogene α (gro-α) | Human ovarian carcinoma (HEY) xenograft                                                           | [153]     |
| **CD3**           | Cluster of differentiation 3                                               | Anti-CD3 scFvs                                                                | Two scFvs fused with diphtheria toxin fragment (A-dmDT390-bisFv, or UCHT1) | Patients with cutaneous T cell lymphoma                                                           | [154]     |
| **CD19**          | Cluster of differentiation 19, or B-Lymphocyte Surface Antigen B4           | mAb huB4                                                                       | huB4 mAb conjugated with cytotoxic agent maytansinoid DM4 (Colruoximab ravtansine, or SAR3419) | Phase II study in patients with relapsed or refractory acute lymphoblastic leukemia | [155]     |
| Target | Designation | Targeting Agent | Agent | Patients Group/Animal Model | Reference |
|--------|-------------|-----------------|-------|-----------------------------|-----------|
| CD22   | Cluster of differentiation 22 | Inotuzumab | Inotuzumab conjugated with cytotoxic agent calicheamicin (Inotuzumab Ozogamicin) | FDA approved for the treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (Besponsa®, Pfizer, Inc., New York, NY, USA) | [156] |
|        |             | anti-CD22 Fv    | anti-CD22 Fv fused with *Pseudomonas* exotoxin A fragment (recombinant immunotoxin Moxetumomab pasudotox) | FDA approved for the treatment of patients with relapsed or refractory hairy cell leukemia (Lumoxiti®, AstraZeneca PLC, Cambridge, UK) | [157] |
| CD25   | Cluster of differentiation 25, or Interleukin-2 receptor alpha chain | anti-CD25 scFv | anti-CD25 scFv fused with *Pseudomonas* exotoxin A fragment (anti-Tac(Fv-PE38), or LMB-2) | Phase II study patients with adult T-cell leukemia | [158] |
| CD30   | Cluster of differentiation 30, or TNF receptor superfamily member 8 | Brentuximab | Brentuximab conjugated with antimitotic agent monomethyl auristatin E (MMAE) (Brentuximab vedotin) | FDA approved for the treatment of patients with classical Hodgkin lymphoma and anaplastic large-cell lymphoma (Adcetris®, Seattle Genetics, Inc., Bothell, WA, USA) | [159] |
| CD46   | Cluster of differentiation 46, or Membrane cofactor protein | mAb 23AG2 | 23AG2 mAb conjugated with cytotoxic agent monomethyl auristatin F (MMAF) | Human multiple myeloma disseminated xenograft (RPMI8226) | [160] |
| CD56   | Cluster of differentiation 56, or Neural cell adhesion molecule | Lorvotuzumab | Lorvotuzumab conjugated with maytansinoid cytotoxic agent (DM1) (Lorvotuzumab mertansine, or IMGN901) | Phase I study in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma | [161] |
| Target | Designation | Targeting Agent | Agent | Patients Group/Animal Model | Reference |
|--------|-------------|----------------|-------|-----------------------------|-----------|
| CD70   | Cluster of differentiation 70, or TNF ligand superfamily member 7 | mAb h1F6 | h1F6 mAb conjugated with dimeric pyrrolobenzodiazepine (h1F6239C-PBD) | Renal cell carcinoma and non-Hodgkin lymphoma xenografts | [162] |
| CD74   | Cluster of differentiation 74, or HLA class II histocompatibility antigen gamma chain | mAb hLL1 | hLL1 mAb conjugated with drug Doxorubicin (IMMU-110) | Human multiple myeloma (MC-CAR) xenograft | [163] |
| BCMA   | B-cell maturation antigen | mAb J6M0 | J6M0 mAb conjugated with cytotoxin agent monomethyl auristatin F (MMAF) (J6M0-mcMMAF) | Human multiple myeloma subcutaneous xenografts (H929 and OPM2) and orthotopic disseminated xenografts (MM1S) | [164] |
EGFR (HER1-4) epidermal growth factor receptor family is the most studied in terms of involvement in tumor metabolism and targeting fitness. Overexpression of receptors of this family is characteristic for many types of carcinomas, including breast, lung, stomach, brain and some other cancers [165,166]. EGFR/HER1, HER2 and HER3 receptors are successfully used as targets for targeted delivery of various antitumor agents [167]. To date there is only one FDA approved anti-tumor agent targeted to the EGFR family member, excluding non-conjugated therapeutic antibodies from consideration. Kadcyla® is based on an antibody specific for HER2 (Trastuzumab) and an antimitotic agent emtansine (DM1) inhibiting the polymerization of microtubules that are chemically linked together via a non-reducible thioether linker. This agent is used for the second line treatment of HER2-positive metastatic breast cancer.

Clinical and preclinical trials of Kadcyla® are underway for other types of HER2-overexpressing tumors, for example, for monotherapy of metastatic breast cancer and for therapy of gastric cancer in patients previously treated with taxane drugs [168].

Chemical conjugation allows obtaining targeted agents of various specificity with different toxic/cytostatic moieties. For example, this approach is used to create EGFR-specific agents for boron neutron capture therapy of brain tumors, which are now undergoing preclinical trials [169,170]. Chemical conjugation of functional modules has its drawbacks such as manufacturing difficulties and varying composition. Progress in genetic engineering has allowed the creation of recombinant antitumor agents where protein toxins of various origins and the mechanism of action are fused with a targeting moiety into a single polypeptide chain. The wide spectrum of recombinant antitumor agents specific to EGFR family receptors undergo clinical [171–174] and preclinical trials [131,135,136,175–185].

Tumor development is accompanied by angiogenesis which is naturally associated with the high expression of vascular endothelial growth factor receptors (VEGFR 1–3) and integrins (αvβ3 and others), mainly on endothelial cells [186]. The applicability of these receptors as target molecules is twofold: they can be used for targeted drug delivery and as the direct means for the tumor disruption by restriction of nutrients supply [187–189]. VEGF-receptors are often present in a prostate cancer, melanoma and leukemia. The examples of other growth factor receptors associated with tumor development and used as targets are platelet growth factor receptor PDGFRα/β [142] and insulin-like growth factor receptor IGF-1R [144].

Rapidly dividing cancer cells are in a great need for iron so the increased expression of transferrin (iron-binding protein) receptors, TfR1-2 is reported for brain, lung, bladder, intestine, pancreas, and some other cancers [190,191]. Thus targeted drug delivery can be performed using both transferrin itself and antibodies to its receptor as a targeting moiety [191–193]. Similarly, a significant proportion of fast-growing tumors are characterized by high expression of receptors for folic acid [194,195], biotin [196,197], and other vitamins, as well as membrane carriers of sugars [198–200].

In case of blood cancers, including various forms of lymphoma, leukemia and myeloma, the lymphocyte antigens and a number of other proteins which are overexpressed on the surface of transformed cells are employed as molecular targets. Disseminated nature of such tumors promoted the implementation of the targeted approach to treatment. To date, a wide number of molecular targets, including clusters of differentiation CD3, CD19, CD20, CD22, CD25, CD27, CD30, CD33, CD37, CD40, CD52, CD56, CD70, CD74, CD79, CD80, CD138, CD307, and B-cell maturation antigen BCMA, and some other have been tested (with varying success) for the drug delivery to hematological tumors (for details see reviews: [201–203]).

The range of potential targets has significantly expanded in recent years. Thus, it has been shown that aberrant expression and activation of a number of members of G-protein-coupled receptor family plays an important role in carcinogenesis, tumor growth and invasion, cell migration and metastasis.

The most studied proteins of this group are receptors of angiotensin, lysophosphatidic acid, sphingosin-1-phosphate, melanocortin, vasopressin, estrogen, gastrin-releasing peptide, etc. [9,204]. This extensive group of receptors is of great interest and, apparently, the number of targeted agents specific to them will rapidly increase in the nearest future.
Several other molecular targets ought to be mentioned: interleukin receptors expressed, particularly, in some types of gliomas [205]; mesothelin which is involved in cell adhesion and is highly expressed on mesothelioma cells and in a number of adenocarcinomas [206,207]; prostate-specific membrane antigen PSMA [208,209]; plasma membrane proteoglycans, for example the mucin (MUC-1) overexpressed in carcinomas [210,211]. The altered glycosylation profile of the tumor cells surface makes them possible to be recognized by lectins [212].

The above listed molecules are expressed on the surface of tumor cells. However, stromal components of a tumor, both nonmalignant cells and extracellular matrix (ECM), can also serve as a target for directional treatment. Tumor progression is strongly determined by the microenvironment of tumor cells and crosstalk between tumor cells, cancer associated fibroblasts, endothelial cells, pericytes, and smooth muscle cells composing tumor vasculature, as well as infiltrating immune and inflammatory cells [213]. Targeting non-malignant cells of tumor stroma (including their signaling pathway participants) [214–216] and vasculature [217–219] seems to be the potent treatment approach with most remarkable progress in immune checkpoints inhibition [220].

To date, the existing treatment strategies are mostly aimed at improvement in blood perfusion, drug extravasation and tissue penetration by modulating of tumor stroma as well as at activation of the antitumor immune response [221,222]. However, the specificity of tumor microenvironment makes it potentially possible to develop the approaches for drug delivery based on targeting stromal compartment. For example, a number of antiangiogenic nanoparticle-based agents with receptor specific peptides have been reported [223,224].

The list of aforementioned cancer-specific molecular targets is far from complete. The development of molecular oncology and the gradual deciphering of the mechanisms responsible for cells transformation and regulation of their malignant phenotype lead to the formulation of new principles and approaches to control tumor progression and eliminate tumor cells. It can be said that currently there is an active search for new targets that would provide effective antitumor treatment [225,226].

3.2. Targeting Agents

Antibodies and their recombinant derivatives are target-recognizing molecules most commonly used for drug delivery to tumor [227,228]. Historically, the first antibody fragment were obtained by hydrolytic cleavage of a full-size antibody and included one or two antigen-binding domains (Fab and (Fab)_2, respectively) [229]. The development of recombinant protein technology lead to creation of scFv-type (single chain fragment variable) fragments represented by variable domains of the heavy and light chains fused together by a peptide linker [230,231], and dsFv-type (Disulfide-stabilized fragment variable) fragments in which the variable domains are linked by a disulfide bond [232,233]. Single-chain antibodies of the Camelidae family and Chondrichthyes class were used to construct single-domain antibodies (sdAb or nanobodies) [234]. The major advantage of recombinant antibody fragments is the possibility of their genetic fusion with other proteins in order to create multivalent and/or multispecific agents [235–237]. A plethora of targeted antitumor agents based on antibodies derivatives are under preclinical efficiency trials. There are some promising results obtained for scFv-based [128,183,238], dsFv-based [148,239,240], nanobody-based [184,241] immunotoxins. Antibody fragments are also widely used as a targeting moiety of hybrid multifunctional complexes with QDs, superparamagnetic iron-oxide, gold nanoparticles, etc. [101,107,242].

Although antibody-based agents are indisputably potent drug targeting units there is a promising alternative represented by non-immunoglobulin scaffold proteins which also have hypervariable sites responsible for highly specific target recognition [243–245]. These proteins possess several advantages compared to antibodies: they have no propensity to aggregate and commonly are highly thermodynamically stable so they are less susceptible to the external factors such as temperature, pH, and protease activity [246]. The valuable characteristic of non-immunoglobulin scaffold proteins is their smaller size. Targeting moieties based on adnectins, affibodies, DARPin, and knottins are successfully tested [132,139,141,143,247–249]. The next promising group is represented by fynomers [250,251],
anticalins, and Kunitz domains (modified Kunitz-type inhibitors) which demonstrated high binding capacity and can be potentially applied for targeted delivery of various agents [252,253].

In the case when the molecular target is represented by membrane receptor, the delivered agent can be conjugated directly to the ligand of this receptor. This approach is widely used to antitumor agent design both in case when the targeting moiety is a low molecular weight compound (folate, carbohydrate residues, vitamins etc.) [147,194,254] or a protein (transferrin, growth factors) [131,255].

Finally, it is worth mentioning peptides as a means of targeted drug delivery. These peptides may be divided into two groups. The first group is represented by tumor-homing peptides (THPs) which are capable of specific recognition of certain tumor-associated antigens. The best-known THP is RGD (Arg-Gly-Asp) binding to integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$, which are widely present on the surface of endothelial cells of tumor vessels [256]. This sequence was first discovered as minimal binding epitope of fibronectin [257]. To date two forms of RGD peptides are being investigated: linear tri-heptapeptides and cyclic motifs. The structural rigidity of cyclic RGD peptides conditions their elevated specificity to receptor subtypes compared to linear peptides, they are also less susceptible to degradation [258,259].

Internalizing RGD (iRGD) peptides with 9-amino acid cyclic motifs was shown to launch transcytosis of nano-carriers through the vascular endothelium. This allows delivering loaded nano-carriers to the tumors with non-leaky vasculature where the EPR based delivery strategy is not applicable. A significant improvement of drug delivery and hence antitumor efficacy has been shown for a wide variety of nano-carriers in multiple tumor models [260], both in case when the iRGD-peptide was chemically bound to the nano-carrier [261,262] or co-administered [263].

Among cell penetrating peptides chlorotoxins or CTX-like peptides (a group of peptides derived from the scorpion venom) is intensely studied as targeting agents for targeted drug delivery. CTX peptide was purified and characterized in early 1990s [264] and then was shown to specifically bind to glioma cells [265]. The further research in this area indicated that CTX-like peptides can be internalized both by the energy-dependent (endocytosis) and by the energy-independent way. It was also shown that CTX-like peptides have a tumor binding activity, but their molecular target is not yet specified; nevertheless chlorine channels, matrix metalloproteinase-2 and annexin A2 are considered as potential candidates. Currently, the use of CTX-like peptides is investigated for various types of tumors (mainly for brain tumors) for imaging, drug delivery and radiotherapy [266,267].

Another representatives of the THP group are transferrin receptor-specific peptides (7pep, HAIYPRH), peptides having R/KXXR/K motif, which undergo neurophilin mediated internalization, and many others, including artificially synthesized peptides [268,269].

The second group of peptides with high potential for targeted drug delivery is represented by cell-penetrating peptides (CPPs) which are non-homologous peptides composed with 5–30 a.a. and originated from different organisms including humans. The common property of these peptides is the ability to penetrate the cell membrane by endocytosis or direct translocation. The penetration mechanism is not yet fully comprehended, but obviously is associated with the presence of cationic amino acid residues in the peptides. Cell-penetrating peptides have no binding selectivity to cells of a specific molecular profile but significantly facilitate cell entry [270,271].

Thus, active drug delivery to tumor cells is an intensively developing approach. Active search for new targets, development of targeting moieties specific to them and employing of various toxic and/or imaging moieties led to an explosive growth of a number of candidate antitumor agents in recent years. The spectrum of delivered agents extends from cytostatic drugs such as DM-1, doxorubicin, maytansinoid [140,147,155], truncated plant and bacterial toxins e.g., gelonin and Pseudomonas exotoxin A [128,131], radionuclides mostly for imaging purposes ($^{99}$Tc, $^{111}$In, $^{68}$Ga) [133,138], up to photosensitizing dyes e.g., porphyrin, phthalocyanine [272,273] and nanoparticles of different nature (QDs, carbon, polymer, gold nanoparticles, UCNPs) [101,139,144,151,152,272]. The latter group, targeted nanoparticle-based drugs, is particularly attractive for producing hybrid multifunctional complexes combining properties of imaging and therapeutic agent.
4. Cell-Mediated Targeting

In recent years, a new approach has been proposed implying drug delivery by cells which possess preferential tropism to tumor (Figure 3).

This approach possesses some distinct advantages: it allows active delivery of the loaded drug directionally to the target site, prolonged half-life, gradual and controlled release and decreased side cytotoxicity and immunogenicity [11]. Certain cell populations are able to infiltrate a tumor despite an increased interstitial pressure and the presence of a tumor stroma. Gradients of cytokines (macrophage colony-stimulating factor CSF1, pro-inflammatory cytokines), chemokines (particularly those which are recognized by the CXCR4/CXCL12 receptor system, as well as the MCP-1 monocyte chemotactic protein) and growth factors (VEGF, TGF-β and fibroblast growth factor FGF-2) can act as cell attractants [274]. To date, several cell types have been tested as drug carriers. Thus, naive T-cells tropic to lymph nodes were successfully used to attack tumors of this localization [275]. Primed T-cells specific to a certain tumor cell surface antigen can be used in case of tumors of other localizations [276]. In addition, cytokine and growth factor gradients direct the migration of some cell types, which allows using them as drug carriers. Monocytes and neutrophils [277–279], macrophages [280,281], as well as mesenchymal stem cells from bone marrow and cord blood [282,283], neural stem cells [284,285] and some other cell types were successfully applied for antitumor agents delivery.

![Figure 3. Scheme illustrating the principle of cell-mediated tumor targeting. Drug carriers may be tumor tropic cells: naive T-lymphocytes, primed T-lymphocytes, monocytes, neutrophilic granulocytes, macrophages, mesenchymal stem cells from bone marrow and umbilical cord blood, neural stem cells, and some other cell types. This approach involves the collection of autologous or donor material, loading/activation of the cells under ex vivo conditions, expansion to necessary quantities and introducing them back into the body. Cells can be successfully used to deliver low-molecular compounds, proteins, genetic material, nanoparticles and oncolytic viruses.](image-url)

The procedure is basically associated with the collection of autologous or donor material, ex vivo cell loading/activation, expansion the cells to the required quantities and administration to the patient. Cell-mediated approach provides delivery of low-molecular compounds, proteins, genetic material, nanoparticles and oncolytic viruses possible [286–288]. Recently developed T-cell genetic “reprogramming” using CAR (chimeric antigen receptor) technology producing cells with designed specificity to antigens and intended to activate antitumor immunity (see review: [289]) seems to be also promising when combined with cell loading by antitumor agents.

Although a significant success was achieved in this area, there are still some limitations which ought to be considered and overcome. They are associated both with the method procedure and specific properties of the cells acting as drug carriers. Methodological limitations include the risk...
of the carrier-cells contamination during cultivation and loading with possible subsequent blood contamination, drug loading difficulties e.g., low loading capacity and disintegration within the carrier-cell, limited control of drug release. Cell type specific limitations are generally represented by short ex vivo life, impaired resistance to damaging factors (mechanical or osmotic) induced by loading procedures and cultivation difficulties. Thus, platelets are prone to induce thrombogenesis, leucocytes are characterized by poor transduction level, stem cells tend to lose potency in vitro [290]. It must be noted that many technologies from this group are directly related to the production of tumoricidal cells.

5. Conclusions

The rapid accumulation of knowledge on the mechanisms driving carcinogenesis and peculiar features of tumor growth lead to development of a number of approaches to the targeted delivery of therapeutic agents to tumor cells or to the newly formed tumor vasculature. The opportunity of choosing the most appropriate treatment method which takes molecular and histomorphological tumor features into account and precise adjustment of administration schedule and regime is moving us towards ideals of personalized medicine.

Despite the significant progress in the area and the creation of an unprecedentedly wide range of targeted agents which are now at the clinical or pre-clinical trials, it is necessary to admit that there is still a huge range of outstanding issues. Thus methods to increase passive targeting efficiency and reduce drug dissipation (an unwanted capture by liver or kidney excretion) have to be developed. There is a direct relationship between half-time of blood circulation and the efficiency of passive delivery. The commonly proposed coating of the delivered agent with poly(ethylene)glycol (PEG) or its analogs has now been being critically revised. Such type of coating is intended to prolong circulation time by prevention of protein opsonization on the agent surface and following capturing of the agent by macrophages [291]. However, about 30 years of clinical experience resulted in elucidating possible side effects and complications, including registered cases of hypersensitivity, unexpected effects on drug pharmacokinetics, non-biodegradability and possible accumulation in the body, toxic side products, and production of anti-PEG antibodies [292–294]. Nowadays the problem of a protein corona formation on the nano-sized agents and its impact on a biological identity including specificity to target cells and retention in pathological sites is among the highly attractive for research community. The proposed ways to optimize blood circulation time and enhance the delivery efficiency vary from using low adhesive coatings which prevent protein binding [295,296] to preconditioning of the delivered agent with proteins such as albumin before they are administered in to the blood stream to artificially produce protein corona with desired prosperities [297,298].

Another perspective approach is to improve the delivery efficiency is to affect the tumor microenvironmental processes, especially angiogenesis and oxygenation. Antiangiogenic drugs block invasion of new vessels into the tumor and can temporarily normalize tumor vasculature and hence the oxygenation level. This leads to a reduction of tumor interstitial pressure, improved drug delivery, and the realization of the “oxygen effect” during radiotherapy [299,300].

The common limitation of drug delivery to solid tumors is a poor penetration of the any agents into the deep of the tumor mass [301]. The approach has been proposed to improve the penetration efficiency by simultaneous targeting the tight junctions which are widely represented in solid tumors. Several protein agents targeting intercellular tight junctions has been created and demonstrated its potency in combination with various agents [302–304]. This approach is of particular interest when applying targeted agents specifically binding to cell surface receptors, since the latter are often hidden under cell adhesion proteins and may be unavailable for binding.

To summarize, the progress in understanding intratumoral transport of nutrients and metabolites, tumor peculiarities at molecular and cellular level, growing list of potential molecular targets of tumor cells, extending amount of data elucidating tumor interaction with cells of immune system allow
to expect generation of novel ideas and solutions to overcome encountered issues and to improve antitumor drug delivery and treatment efficiency.

**Author Contributions:** Conceptualization, I.V.B.; data curation, E.L.G., I.V.B.; Writing—Original Draft preparation, O.M.K., E.L.G., R.A., I.V.B.; Writing—Review and Editing, O.M.K., E.A.S., I.V.B., supervision, I.V.B.

**Funding:** This research and the APC were funded by the Ministry of Science and Higher Education of the Russian Federation, grant number RFMEFI58418x0033.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* 2011, 144, 646–674. [CrossRef] [PubMed]
2. Fong, E.L.; Harrington, D.A.; Farach-Carson, M.C.; Yu, H. Heralding a new paradigm in 3D tumor modeling. *Biomaterials* 2016, 108, 197–213. [CrossRef] [PubMed]
3. Weeber, E.; Ooft, S.N.; Dijkstra, K.K.; Voest, E.E. Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery. *Cell Chem. Biol.* 2017, 24, 1092–1100. [CrossRef] [PubMed]
4. Sokolova, E.A.; Vodeneev, V.A.; Deyev, S.M.; Balalaeva, I.V. 3D in vitro models of tumors expressing EGFR family receptors: A potent tool for studying receptor biology and targeted drug development. *Drug Discov. Today* 2018. [CrossRef] [PubMed]
5. Rankin, E.B.; Giaccia, A.J. Hypoxic control of metastasis. *Science* 2016, 352, 175–180. [CrossRef] [PubMed]
6. Nagelkerke, A.; Bussink, J.; Rowan, A.E.; Span, P.N. The mechanical microenvironment in cancer: How physics affects tumours. *Semin. Cancer Biol.* 2015, 35, 62–70. [CrossRef] [PubMed]
7. Corbet, C.; Feron, O. Tumour acidosis: From the passenger to the driver’s seat. *Nat. Rev. Cancer* 2017, 17, 577–593. [CrossRef]
8. Witsch, E.; Sela, M.; Yarden, Y. Roles for growth factors in cancer progression. *Physiology* 2010, 25, 85–101. [CrossRef]
9. Liu, Y.; An, S.; Ward, R.; Yang, Y.; Guo, X.X.; Li, W.; Xu, T.R. G protein-coupled receptors as promising cancer targets. *Cancer Lett.* 2016, 376, 226–239. [CrossRef]
10. Trapani, G.; Denora, N.; Trapani, A.; Laquintana, V. Recent advances in ligand targeted therapy. *J. Drug Target.* 2012, 20, 1–22. [CrossRef]
11. Batrakova, E.V.; Gendelman, H.E.; Kabanov, A.V. Cell-mediated drug delivery. *Expert Opin. Drug Deliv.* 2011, 8, 415–433. [CrossRef] [PubMed]
12. Folkman, J. Tumor angiogenesis: Therapeutic implications. *N. Engl. J. Med.* 1971, 285, 1182–1186. [CrossRef] [PubMed]
13. Siemann, D.W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. *Cancer Treat. Rev.* 2011, 37, 63–74. [CrossRef]
14. Forster, J.C.; Harriss-Phillips, W.M.; Douglass, M.J.; Bezak, E. A review of the development of tumor vasculature and its effects on the tumor microenvironment. *Hypoxia* 2017, 5, 21–32. [CrossRef] [PubMed]
15. Konerding, M.A.; Fait, E.; Gaumann, A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. *Br. J. Cancer* 2001, 84, 1354–1362. [CrossRef]
16. Dewhirst, M.W.; Kimura, H.; Rehmus, S.W.; Braun, R.D.; Papahadjopoulos, D.; Hong, K.; Secomb, T.W. Microvascular studies on the origins of perfusion-limited hypoxia. *Br. J. Cancer* 1996, 27, S247–S251.
17. McDonald, D.M.; Choyke, P.L. Imaging of angiogenesis: From microscope to clinic. *Nat. Med.* 2003, 9, 713–725. [CrossRef]
18. Leu, A.J.; Berk, D.A.; Lymboussaki, A.; Alitalo, K.; Jain, R.K. Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation. *Cancer Res.* 2000, 60, 4324–4327.
19. Padera, T.P.; Kadambi, A.; di Tomaso, E.; Carreira, C.M.; Brown, E.B.; Boucher, Y.; Choi, N.C.; Mathisen, D.; Wain, J.; Mark, E.J.; et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. *Science* 2002, 296, 1883–1886. [CrossRef]
20. Padera, T.P.; Meijer, E.F.; Munn, L.L. The Lymphatic System in Disease Processes and Cancer Progression. *Annu. Rev. Biomed. Eng.* 2016, 18, 125–158. [CrossRef]
21. Maniotis, A.J.; Folberg, R.; Hess, A.; Seftor, E.A.; Gardner, L.M.; Pe’er, J.; Trent, J.M.; Meltzer, P.S.; Hendrix, M.J. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. *Am. J. Pathol.* 1999, 155, 739–752. [CrossRef]

22. Folberg, R.; Maniotis, A.J. Vasculogenic mimicry. *Acta Pathol. Microbiol. Immunol. Scand.* 2004, 112, 508–525. [CrossRef]

23. Vaupel, P.; Hockel, M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: Characterization and therapeutic relevance. *Int. J. Oncol.* 2000, 17, 869–879. [CrossRef]

24. Wijffels, K.I.; Kaanders, J.H.; Rijken, P.F.; Bussink, J.; van den Hoogen, F.J.; Marres, H.A.; de Wilde, P.C.; Raleigh, J.A.; van der Kogel, A.J. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. *Br. J. Cancer* 2000, 83, 674–683. [CrossRef]

25. Beasley, N.J.; Wykoff, C.C.; Watson, P.H.; Leek, R.; Turley, H.; Gatter, K.; Pastorek, J.; Cox, G.J.; Ratcliffe, P.; Harris, A.L. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. *Cancer Res.* 2001, 61, 5262–5267.

26. Hoogsteen, I.J.; Lok, J.; Marres, H.A.; Takes, R.P.; Rijken, P.F.; van der Kogel, A.J.; Kaanders, J.H. Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia. *Eur. J. Cancer* 2009, 45, 2906–2914. [CrossRef] [PubMed]

27. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. *Nature* 2000, 407, 249–257. [CrossRef] [PubMed]

28. Gee, M.S.; Procopio, W.N.; Makonnen, S.; Feldman, M.D.; Yeilding, N.M.; Lee, W.M. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. *Am. J. Pathol.* 2003, 162, 183–193. [CrossRef]

29. Hobbs, S.K.; Monsky, W.L.; Yuan, F.; Roberts, W.G.; Griffith, L.; Torchilin, V.P.; Jain, R.K. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. *Proc. Natl. Acad. Sci. USA* 1998, 95, 4607–4612. [CrossRef]

30. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J.W.; Thurston, G.; Roberge, S.; Jain, R.K.; McDonald, D.M. Openings between defective endothelial cells explain tumor vessel leakiness. *Am. J. Pathol.* 2000, 156, 1363–1380. [CrossRef]

31. Rippe, B.; Rosengren, B.I.; Carlsson, O.; Venturoli, D. Transendothelial transport: The vesicle controversy. *J. Vasc. Res.* 2002, 39, 375–390. [CrossRef] [PubMed]

32. Maeda, H.; Noguchi, Y.; Sato, K.; Akaike, T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. *Jpn. J. Cancer Res.* 1994, 85, 331–334. [CrossRef] [PubMed]

33. Weidensteiner, C.; Reichardt, W.; Shami, P.J.; Saavedra, J.E.; Keefer, L.K.; Baumer, B.; Werres, A.; Jasinski, R.; Osterberg, N.; Weyerbrock, A. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. *Nitric Oxide* 2012, 30, 17–25. [CrossRef] [PubMed]

34. Okada, F. Beyond foreign-body-induced carcinogenesis: Impact of reactive oxygen species derived from inflammatory cells in tumorigenic conversion and tumor progression. *Int. J. Cancer* 2007, 121, 2364–2372. [CrossRef] [PubMed]

35. Gu, Y.T.; Xue, Y.X.; Wang, Y.F.; Wang, J.H.; ShangGuan, Q.R.; Zhang, J.X.; Qin, L.J. Role of ROS/RhoA/PI3K/PIKB signaling in NS1619-mediated blood-tumor barrier permeability increase. *J. Mol. Neurosci.* 2012, 48, 302–312. [CrossRef] [PubMed]

36. Fang, J.; Qin, H.; Nakamura, H.; Tsukigawa, K.; Shin, T.; Maeda, H. Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors. *Cancer Sci.* 2012, 103, 535–541. [CrossRef]
39. Tanaka, S.; Akaike, T.; Wu, J.; Fang, J.; Sawa, T.; Ogawa, M.; Beppu, T.; Maeda, H. Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium. J. Drug Target. 2003, 11, 45–52. [CrossRef]

40. Wu, J.; Akaike, T.; Hayashida, K.; Okamoto, T.; Okuyama, A.; Maeda, H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn. J. Cancer Res. 2001, 92, 439–451. [CrossRef]

41. Deryugina, E.I. Chorioallantoic Membrane Microtumor Model to Study the Mechanisms of Tumor Angiogenesis, Vascular Permeability, and Tumor Cell Intravasation. Methods Mol. Biol. 2016, 1430, 283–298. [CrossRef] [PubMed]

42. Murohara, T.; Horowitz, J.R.; Silver, M.; Tsurumi, Y.; Chen, D.; Sullivan, A.; Isner, J.M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998, 97, 99–107. [CrossRef] [PubMed]

43. Kano, M.R.; Bae, Y.; Iwata, C.; Morishita, Y.; Yashiro, M.; Oka, M.; Fujii, T.; Komuro, A.; Kiyono, K.; Kaminiishi, M.; et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc. Natl. Acad. Sci. USA 2007, 104, 3460–3465. [CrossRef] [PubMed]

44. Seki, T.; Carroll, F.; Illingworth, S.; Green, N.; Cawood, R.; Bachtarzi, H.; Subr, V.; Fisher, K.D.; Seymour, L.W. Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. J. Controll. Release 2011, 156, 381–389. [CrossRef] [PubMed]

45. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387–6392. [PubMed]

46. Maeda, H. The link between infection and cancer: Tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci. 2013, 104, 779–789. [CrossRef]

47. Maeda, H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 2015, 91, 3–6. [CrossRef]

48. Maeda, H. Polymer therapeutics and the EPR effect. J. Drug Target. 2017, 25, 781–785. [CrossRef]

49. Wang, J.; Sui, M.; Fan, W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr. Drug Metab. 2010, 11, 129–141. [CrossRef]

50. Golombek, S.K.; May, J.N.; Theek, B.; Appold, L.; Drude, N.; Kiessling, F.; Lammers, T. Tumor targeting via EPR: Strategies to enhance patient responses. Adv. Drug Deliv. Rev. 2018, 130, 17–38. [CrossRef]

51. Rosenblum, D.; Joshi, N.; Tao, W.; Karp, J.M.; Peer, D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun. 2018, 9, 1410. [CrossRef] [PubMed]

52. Working, P.K.; Dayan, A.D. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Hum. Exp. Toxicol. 1996, 15, 751–785. [PubMed]

53. Batist, G.; Ramakrishnan, G.; Rao, C.S.; Chandrasekharan, A.; Gatheil, J.; Guthrie, T.; Shah, P.; Khojasteh, A.; Nair, M.K.; Hoelzer, K.; et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 2001, 19, 1444–1454. [CrossRef]

54. Petre, C.E.; Dittmer, D.P. Liposomal daunorubicin as treatment for Kaposi’s sarcoma. Int. J. Nanomed. 2007, 2, 277–288.

55. Yingchoncharoen, P.; Kalinowski, D.S.; Richardson, D.R. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol. Rev. 2016, 68, 701–787. [CrossRef] [PubMed]

56. Bulbake, U.; Doppalapudi, S.; Kommineni, N.; Khan, W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmacuetics 2017, 9, 12. [CrossRef] [PubMed]

57. Hardiansyah, A.; Huang, L.Y.; Yang, M.C.; Liu, T.Y.; Tsai, S.C.; Yang, C.Y.; Kuo, C.Y.; Chan, T.Y.; Zou, H.M.; Lian, W.N.; et al. Magnetic liposomes for colorectal cancer cells therapy by high-frequency magnetic field treatment. Nanoscale Res. Lett. 2014, 9, 497. [CrossRef] [PubMed]

58. Chen, X.; Zhang, Y.; Tang, C.; Tian, C.; Sun, Q.; Su, Z.; Xue, L.; Yin, Y.; Ju, C.; Zhang, C. Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis. Int. J. Pharm. 2017, 529, 102–115. [CrossRef] [PubMed]
59. Chi, Y.; Yin, X.; Sun, K.; Feng, S.; Liu, J.; Chen, D.; Guo, C.; Wu, Z. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. J. Controll. Release 2017, 261, 113–125. [CrossRef] [PubMed]

60. Pourhassan, H.; Clergeaud, G.; Hansen, A.E.; Ostrem, R.G.; Fliedner, F.P.; Melander, F.; Nielsen, O.L.; O’Sullivan, C.K.; Kjaer, A.; Andresen, T.L. Revisiting the use of sPLA2-sensitive liposomes in cancer therapy. J. Controll. Release 2017, 261, 163–173. [CrossRef] [PubMed]

61. Deyev, S.; Proshkina, G.; Baryshnikova, O.; Ryabova, A.; Avishai, G.; Katrivas, L.; Giannini, C.; Levi-Kalisman, Y.; Kotlyar, A. Selective staining and eradication of cancer cells by protein-carrying DARPin-functionalized liposomes. Eur. J. Pharm. Biopharm. 2018, 130, 296–305. [CrossRef] [PubMed]

62. Salkho, N.M.; Paul, V.; Kawak, P.; Vitor, R.F.; Martins, A.M.; Al Sayah, M.; Husseini, G.A. Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy. Artif. Cells Nanomed. Biotechnol. 2018, 1–11. [CrossRef] [PubMed]

63. Yudintsev, A.V.; Shilyagina, N.Y.; Dyakova, D.V.; Lermontova, S.A.; Klapshina, L.G.; Guryev, E.L.; Balalaeva, I.V.; Vodeneev, V.A. Liposomal Form of Tetra(Aryl)Tetracyanoporphyrazine: Physical Properties and Photodynamic Activity In Vitro. J. Fluoresc. 2018, 28, 513–522. [CrossRef]

64. Fasano, M.; Curry, S.; Terreno, E.; Galliano, M.; Fanali, G.; Narciso, P.; Notari, S.; Ascenzi, P. The extraordinary ligand binding properties of human serum albumin. JUBMB Life 2005, 57, 787–796. [CrossRef] [PubMed]

65. Elzoghby, A.O.; Samy, W.M.; Elgindy, N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Controll. Release 2012, 157, 168–182. [CrossRef]

66. Goldstein, D.; El-Maraghi, R.H.; Hammel, P.; Heinemann, V.; Kunzmann, V.; Sastre, J.; Scheithauer, W.; Siena, S.; Tabernero, J.; Teixeira, L.; et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial. J. Natl. Cancer Inst. 2015, 107. [CrossRef] [PubMed]

67. Hirsh, V. nab-Paclitaxel for the management of patients with advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther. 2014, 14, 129–141. [CrossRef] [PubMed]

68. Yamamoto, Y.; Kawano, I.; Iwase, H. nab-Paclitaxel for the treatment of breast cancer: Efficacy, safety, and approval. OncoTargets Ther. 2011, 4, 123–136. [CrossRef]

69. Duan, J.; Hao, Y.; Wan, R.; Yu, S.; Bai, H.; An, T.; Zhao, J.; Wang, Z.; Zhuo, M.; Wang, J. Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments. Thorac. Cancer 2017, 8, 138–146. [CrossRef]

70. Saif, M.W. U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane(R)) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. J. Pancreas 2013, 686–688. [CrossRef]

71. Wan, X.; Zheng, X.; Pang, X.; Zhang, Z.; Jing, T.; Xu, W.; Zhang, Q. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. Int. J. Pharm. 2015, 484, 16–28. [CrossRef] [PubMed]

72. Yu, X.; Di, Y.; Xie, C.; Song, Y.; He, H.; Li, H.; Pu, X.; Lu, W.; Fu, D.; Jin, C. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line. Int. J. Nanomed. 2015, 10, 6825–6834. [CrossRef]

73. Peralta, D.V.; He, J.; Wheeler, D.A.; Zhang, J.Z.; Tarr, M.A. Encapsulating gold nanomaterials into size-controlled human serum albumin nanoparticles for cancer therapy platforms. J. Microencapsul. 2014, 31, 824–831. [CrossRef] [PubMed]

74. Han, J.; Wang, Q.; Zhang, Z.; Gong, T.; Sun, X. Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer. Small 2014, 10, 524–535. [CrossRef] [PubMed]

75. Piao, L.; Li, H.; Teng, L.; Yung, B.C.; Sugimoto, Y.; Brueggemeier, R.W.; Lee, R.J. Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer. Nanomedicine 2013, 9, 122–129. [CrossRef] [PubMed]

76. Choi, S.H.; Byeon, H.J.; Choi, J.S.; Thao, L.; Kim, I.; Lee, E.S.; Shin, B.S.; Lee, K.C.; Youn, Y.S. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J. Controll. Release 2015, 197, 199–207. [CrossRef] [PubMed]

77. Lian, H.; Wu, J.; Hu, Y.; Guo, H. Self-assembled albumin nanoparticles for combination therapy in prostate cancer. Int. J. Nanomed. 2017, 12, 7777–7787. [CrossRef] [PubMed]
78. Klapshina, L.G.; Douglas, W.E.; Grigoryev, I.S.; Ladilina, E.Y.; Shirmanova, M.V.; Mysyagin, S.A.; Balalaeva, I.V.; Zagaynova, E.V. Novel PEG-organized biocompatible fluorescent nanoparticles doped with an ytterbium cyanoporphyrazine complex for biophotonic applications. Chem. Commun. 2010, 46, 8398–8400. [CrossRef]

79. Tyler, B.; Gullotti, D.; Mangraviti, A.; Utsuki, T.; Brem, H. Poly lactic acid (PLA) controlled delivery carriers for biomedical applications. Adv. Drug Deliv. Rev. 2016, 107, 163–175. [CrossRef]

80. Bowerman, C.J.; Byrne, J.D.; Chu, K.S.; Schorzman, A.N.; Keeler, A.W.; Sherwood, C.A.; Perry, J.L.; Luft, J.C.; Darr, D.B.; Deal, A.M.; et al. Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer. Nano Lett. 2017, 17, 242–248. [CrossRef]

81. Grossen, P.; Witzigmann, D.;Sieber, S.; Huwyler, J. Effect of platinum nanoparticles on cell death induced by ultrasound in human lymphoma U937 cells. Ultrason. Sonochem. 2016, 31, 206–215. [CrossRef]

82. Shibayagina, N.Y.; Peskova, N.N.; Lermontova, S.A.; Brilina, A.A.; Vodeneev, V.A.; Yakimansky, A.V.; Klaphsina, L.G.; Balalaeva, I.V.; Ladilina, E.Y.; Shirmanova, M.V.; Myagin, S.A.; Balalaeva, I.V.; Zagaynova, E.V. Novel PEG-organized biocompatible fluorescent nanoparticles doped with an ytterbium cyanoporphyrazine complex for biophotonic applications. Chem. Commun. 2010, 46, 8398–8400. [CrossRef]

83. Dhawan, B.; Otis, J.; Joice, M.; Kotljar, A.; Thomas, T.P. PSMA-targeted stably linked “dendrimer-glutamate urea-methotrexate” as a prostate cancer therapeutic. Biomacromolecules 2014, 15, 915–923. [CrossRef] [PubMed]

84. Perez, A.K.; Simpson, J.D.; Fletcher, N.L.; Houston, Z.H.; Fuchs, A.V.; Russell, P.J.; Whittaker, A.K.; Darr, D.B.; Deal, A.M.; et al. Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer. Nano Lett. 2017, 17, 242–248. [CrossRef]

85. Khan, M.S.; Talib, A.; Pandey, S.; Bhasare, M.L.; Gedda, G.; Wu, H.F. Folic Acid navigated Silver Selenide nanoparticles for photo-thermal ablation of cancer cells. Colloids Surf. B: Biointerfaces 2017, 159, 564–570. [CrossRef] [PubMed]

86. Jawaid, P.; Rehman, M.U.; Hassan, M.A.; Zhao, Q.L.; Li, P.; Miyamoto, Y.; Misawa, M.; Ogawa, R.; Shimizu, T.; Kondo, T. Effect of platinum nanoparticles on cell death induced by ultrasound in human lymphoma U937 cells. Ultrason. Sonochem. 2016, 31, 206–215. [CrossRef]
97. Feng, Q.; Shen, Y.; Fu, Y.; Muroski, M.E.; Zhang, P.; Wang, Q.; Xu, C.; Lesniak, M.S.; Li, G.; Cheng, Y. Self-Assembly of Gold Nanoparticles Shows Microenvironment-Mediated Dynamic Switching and Enhanced Brain Tumor Targeting. *Theranostics* 2017, 7, 1875–1889. [CrossRef]

98. Deyev, S.; Proshkina, G.; Ryabova, A.; Tavanti, F.; Menziani, M.C.; Eidelstein, G.; Avishai, G.; Kotlyar, A. Synthesis, Characterization, and Selective Delivery of DARPin-Gold Nanoparticle Conjugates to Cancer Cells. *Bioconjugate Chem.* 2017, 28, 2569–2574. [CrossRef]

99. Naha, P.C.; Lau, K.C.; Hsu, J.C.; Hajfathalian, M.; Mian, S.; Chhour, P.; Uppuluri, L.; McDonald, E.S.; Maidment, A.D.; Cormode, D.P. Gold silver alloy nanoparticles (GSAN): An imaging probe for breast cancer screening with dual-energy mammography or computed tomography. *Nanoscale* 2016, 8, 13740–13754. [CrossRef]

100. Zhao, Y.; Pang, B.; Luehmann, H.; Detering, L.; Yang, X.; Sultan, D.; Harpsritte, S.; Sharma, V.; Cutler, C.S.; Xia, Y.; et al. Gold Nanoparticles Doped with (199) Au Atoms and Their Use for Targeted Cancer Imaging by SPECT. *Adv. Healthc. Mater.* 2016, 5, 928–935. [CrossRef]

101. Balalaeva, I.V.; Zdobnova, T.A.; Krutova, I.V.; Brikina, A.A.; Lebedenko, E.N.; Deyev, S.M. Passive and active targeting of quantum dots for whole-body fluorescence imaging of breast cancer xenografts. *J. Biophotonics* 2012, 5, 860–867. [CrossRef] [PubMed]

102. Depan, D.; Misra, R.D. Structural and physicochemical aspects of silica encapsulated ZnO quantum dots with high quantum yield and their natural uptake in HeLa cells. *J. Biomed. Mater. Res. Part A* 2014, 102, 2934–2941. [CrossRef] [PubMed]

103. Balalaeva, I.V.; Zdobnova, T.A.; Sokolova, E.A.; Deyev, S.M. Targeted delivery of quantum dots to the HER2-expressing tumor using recombinant antibodies. *Russ. J. Bioorg. Chem.* 2015, 41, 536–542. [CrossRef]

104. Li, Y.; Zheng, X.; Zhang, X.; Liu, S.; Pei, Q.; Zheng, M.; Xie, Z. Porphyrin-Based Carbon Dots for Photodynamic Therapy of Hepatoma. *Adv. Healthc. Mater.* 2017, 6. [CrossRef] [PubMed]

105. Li, Y.; Zheng, X.; Zhang, X.; Liu, S.; Pei, Q.; Zheng, M.; Xie, Z. Porphyrin-Based Carbon Dots for Photodynamic Therapy of Hepatoma. *Adv. Healthc. Mater.* 2017, 6. [CrossRef] [PubMed]

106. Zhao, Y.; Pang, B.; Luehmann, H.; Detering, L.; Yang, X.; Sultan, D.; Harpsritte, S.; Sharma, V.; Cutler, C.S.; Xia, Y.; et al. Gold Nanoparticles Doped with (199) Au Atoms and Their Use for Targeted Cancer Imaging by SPECT. *Adv. Healthc. Mater.* 2016, 5, 928–935. [CrossRef]

107. Balalaeva, I.V.; Zdobnova, T.A.; Sokolova, E.A.; Deyev, S.M. Targeted delivery of quantum dots to the HER2-expressing tumor using recombinant antibodies. *Russ. J. Bioorg. Chem.* 2015, 41, 536–542. [CrossRef]

108. Li, Y.; Zheng, X.; Zhang, X.; Liu, S.; Pei, Q.; Zheng, M.; Xie, Z. Porphyrin-Based Carbon Dots for Photodynamic Therapy of Hepatoma. *Adv. Healthc. Mater.* 2017, 6. [CrossRef] [PubMed]

109. Ahmadi, Y.; Kostenich, G.; Oron-Herman, M.; Mitterhauser, M.; Orenstein, A.; Mirzaei, S.; Knoll, P. In vivo magnetic resonance imaging of pancreatic tumors using iron oxide nanoworms targeted with PTR86 peptide. *Colloids Surf. B Biointerfaces* 2017, 158, 423–430. [CrossRef]

110. Deyev, S.; Proshkina, G.; Ryabova, A.; Tavanti, F.; Menziani, M.C.; Eidelstein, G.; Avishai, G.; Kotlyar, A. Synthesis, Characterization, and Selective Delivery of DARPin-Gold Nanoparticle Conjugates to Cancer Cells. *Bioconjugate Chem.* 2017, 28, 2569–2574. [CrossRef]

111. Parakhonskiy, B.V.; Haase, A.; Antolini, R. Sub-Micrometer Vaterite Containers: Synthesis, Characterization, and Selective Loading, and Release. *Angew. Chem. Int. Ed.* 2012, 51, 1195–1197. [CrossRef]

112. Abalymov, A.A.; Verkhovskii, R.A.; Novoselova, M.V.; Parakhonskiy, B.V.; Gorin, D.A.; Yashchenok, A.M.; Sukhorukov, G.B. Live-Cell Imaging by Confocal Raman and Fluorescence Microscopy Recognizes the Crystal Structure of Calcium Carbonate Particles in HeLa Cells. *Biotechnol. J.* 2018, 13, e1800071. [CrossRef] [PubMed]
116. Maeda, H.; Khatami, M. Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. *Clin. Transl. Med.* 2018, 7, 11. [CrossRef] [PubMed]

117. O’Brien, M.E.R.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D.G.; Tomczak, P.; Ackland, S.P.; et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX®/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Ann. Oncol.* 2004, 15, 440–449. [CrossRef] [PubMed]

118. Gradishar, W.J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O’Shaughnessy, J. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Breast Cancer. *J. Clin. Oncol.* 2005, 23, 7794–7803. [CrossRef]

119. Gillies, R.J.; Schornack, P.A.; Secomb, T.W.; Raghunand, N. Causes and effects of heterogeneous perfusion in tumors. *Neoplasia* 1999, 1, 197–207. [CrossRef]

120. Jain, R.K. Transport of molecules in the tumor interstitium: A review. *Cancer Res.* 1987, 47, 3039–3051.

121. Natfji, A.A.; Ravishankar, D.; Osborn, H.M.I.; Greco, F. Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection. *J. Pharm. Sci.* 2017, 106, 3179–3187. [CrossRef] [PubMed]

122. Romero-Garcia, S.; Lopez-Gonzalez, J.S.; Baez-Viveros, J.L.; Aguilar-Cazares, D.; Prado-Garcia, H. Tumor cell metabolism: An integral view. *Cancer Biol. Ther.* 2011, 12, 939–948. [CrossRef] [PubMed]

123. DeBerardinis, R.J.; Chandel, N.S. Fundamentals of cancer metabolism. *Cancers* 2019, 12, 068. [CrossRef]

124. Uhlen, M.; Zhang, C.; Lee, S.; Stjohndal, E.; Fagerberg, L.; Bidkhorl, G.; Benfeitas, R.; Arif, M.; Liu, Z.; Edfors, F.; et al. A pathology atlas of the human cancer transcriptome. *Science* 2017, 357. [CrossRef] [PubMed]

125. Bae, Y.H.; Park, K. Targeted drug delivery to tumors: Myths, reality and possibility. *J. Controll. Release* 2011, 153, 198–205. [CrossRef]

126. Zalba, S.; Contreras, A.M.; Haeri, A.; Ten Hagen, T.L.; Navarro, I.; Koning, G.; Garrido, M.J. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. *J. Controll. Release* 2015, 210, 26–38. [CrossRef] [PubMed]

127. Glatt, D.M.; Beckford Vera, D.R.; Prabhu, S.S.; Mumper, R.J.; Luft, J.C.; Benhabbour, S.R.; Parrott, M.C. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy. *Mol. Pharm.* 2015, 12, 5089–5102. [CrossRef]

128. Romero-Garcia, S.; Lopez-Gonzalez, J.S.; Baez-Viveros, J.L.; Aguilar-Cazares, D.; Prado-Garcia, H. Tumor cell metabolism: An integral view. *Cancer Biol. Ther.* 2011, 12, 939–948. [CrossRef] [PubMed]

129. Huang, L.; Gainkam, L.O.; Caveliers, V.; Vanhove, C.; Keyaerts, M.; De Baetselier, P.; Bossuyt, A.; Revets, H.; Lahoutte, T. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. *Mol. Imaging Biol.* 2008, 10, 167–175. [CrossRef] [PubMed]

130. Kruwel, T.; Nevoltris, D.; Bode, J.; Dullin, C.; Baty, D.; Chames, P.; Thepen, T.; Barth, S. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model. *Cancer Immunol. Immunother.* 2012, 61, 1617–1626. [CrossRef]

131. Berstad, M.B.; Cheung, L.H.; Berg, K.; Peng, Q.; Fremstedal, A.S.; Patzke, S.; Rosenblum, M.G.; Weyergang, A. Design of an EGFR-targeting toxin for photochemical delivery: In vitro and in vivo selectivity and efficacy. *Oncogene* 2015, 34, 5582–5592. [CrossRef] [PubMed]

132. Goldstein, R.; Sosabowski, J.; Livano, M.; Leyton, J.; Vigor, K.; Bhavsar, G.; Nagy-Davidescu, G.; Rashid, M.; Miranda, E.; Yeung, J.; et al. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging. *Eur. J. Nucl. Med. Mol. Imaging* 2015, 42, 288–301. [CrossRef]

133. Vaneycken, I.; Devoogdt, N.; Van Gassen, N.; Vincke, C.; Xavier, C.; Wernery, U.; Muyldermans, S.; Lahoutte, T.; Caveliers, V. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. *FASEB J.* 2011, 25, 2433–2446. [CrossRef] [PubMed]

134. Sokolova, E.A.; Zdobnova, T.A.; Stremovskiy, O.A.; Balalaeva, I.V.; Deyev, S.M. Novel recombinant anti-HER2/neu immunotoxin: Design and antitumor efficiency. *Biochemistry* 2014, 79, 1376–1381. [CrossRef]

135. Zalba, S.; Contreras, A.M.; Haeri, A.; Ten Hagen, T.L.; Navarro, I.; Koning, G.; Garrido, M.J. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. *J. Controll. Release* 2015, 210, 26–38. [CrossRef] [PubMed]

136. O’Brien, M.E.R.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D.G.; Tomczak, P.; Ackland, S.P.; et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX®/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Ann. Oncol.* 2004, 15, 440–449. [CrossRef] [PubMed]

137. Gradishar, W.J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O’Shaughnessy, J. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Breast Cancer. *J. Clin. Oncol.* 2005, 23, 7794–7803. [CrossRef]
136. Cao, Y.; Marks, J.W.; Liu, Z.; Cheung, L.H.; Hitelman, W.N.; Rosenblum, M.G. Design optimization and characterization of Her2/neu-targeted immunotoxins: Comparative in vitro and in vivo efficacy studies. *Oncogene* 2014, 33, 429–439. [CrossRef] [PubMed]

137. Sokolova, E.; Proshkina, G.; Kutova, O.; Shilova, O.; Ryabova, A.; Schulga, A.; Stemovskiy, O.; Zdobnova, T.; Balalaeva, I.; Deyev, S. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo. *J. Controll. Release* 2016, 233, 48–56. [CrossRef]

138. Sandberg, D.; Tolmachev, V.; Velikyan, I.; Olofsson, H.; Wennborg, A.; Feldwisch, J.; Carlsson, J.; Lindman, H.; Sorensen, J. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. *Eur. J. Nucl. Med. Mol. Imaging* 2017, 44, 1337–1346. [CrossRef]

139. Guryev, E.L.; Volodina, N.O.; Shilyagina, N.Y.; Gudkov, S.V.; Balalaeva, I.V.; Volovetskii, A.B.; Lyubeshkin, A.V.; Sen, A.V.; Ermilov, S.A.; Vodeneev, V.A.; et al. Radioactive (90)Y upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer. *Proc. Natl. Acad. Sci. USA* 2018, 115, 9690–9695. [CrossRef]

140. Peters, S.; Stahel, R.; Bubendorf, L.; Bonomi, P.; Villegas, A.; Kowalski, D.M.; Baik, C.S.; Isla, D.; Carpeno, J.C.; Garrido, P.; et al. Trastuzumab Emanssine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. *Clin. Cancer Res.* 2018. [CrossRef]

141. Rosestedt, M.; Andersson, K.G.; Mitran, B.; Tolmachev, V.; Lofblom, J.; Orlova, A.; Stahl, S. Affibody-mediated PET imaging of HER3 expression in malignant tumours. *Sci. Rep.* 2015, 5, 15226. [CrossRef] [PubMed]

142. Miller, K.; Dixit, S.; Bredlau, A.L.; Moore, A.; McKinnon, E.; Broome, A.M. Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. *Nanomedicine* 2016, 11, 581–595. [CrossRef] [PubMed]

143. Mitran, B.; Altai, M.; Hofstrom, C.; Honavar, H.; Sandstrom, M.; Orlova, A.; Tolmachev, V.; Graslund, T. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. *Amino Acids* 2015, 47, 303–315. [CrossRef] [PubMed]

144. Li, N.; Zhao, Q.; Shu, C.; Ma, X.; Li, R.; Shen, H.; Zhong, W. Targeted killing of cancer cells in vivo and in vitro with IGF-IR antibody-directed carbon nanohorns based drug delivery. *Int. J. Pharm.* 2015, 478, 644–654. [CrossRef] [PubMed]

145. Xu, L.; Piroillo, K.F.; Tang, W.H.; Rait, A.; Chang, E.H. Transferrin-liposome-mediated systemic pS3 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. *Hum. Gene Ther.* 1999, 10, 2941–2952. [CrossRef] [PubMed]

146. Chatalic, K.L.; Veldhoven-Zweistra, J.; Bolkestein, M.; Hoeben, S.; Koning, G.A.; Boerman, O.C.; de Jong, M.; van Weerden, W.M. A Novel (1)(1)(1)In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. *J. Nucl. Med.* 2015, 56, 1094–1099. [CrossRef]

147. Ikemoto, K.; Shimizu, K.; Ohashi, K.; Takeuchi, Y.; Shimizu, M.; Oku, N. Bauhinia purpurea agglutinin-modified liposomes for human prostate cancer treatment. *Cancer Sci.* 2016, 107, 53–59. [CrossRef]

148. Hassan, R.; Sharon, E.; Thomas, A.; Zhang, J.; Ling, A.; Miettinen, M.; Kreitman, R.J.; Steinberg, S.M.; Hollevoet, K.; Pastan, I. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. *Cancer* 2014, 120, 3311–3319. [CrossRef]

149. Wang, B.; Lv, L.; Wang, Z.; Jiang, Y.; Lv, W.; Liu, X.; Wang, Z.; Zhao, Y.; Xin, H.; Xu, Q. Improved anti-glioblastoma efficacy by IL-13alpha2 mediated copolymer nanoparticles loaded with paclitaxel. *Sci. Rep.* 2015, 5, 16589. [CrossRef]

150. Moore, K.N.; Borghaei, H.; O’Malley, D.M.; Jeong, W.; Seward, S.M.; Bauer, T.M.; Perez, R.P.; Matulonis, U.A.; Running, K.L.; Zhang, X.; et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors. *Cancer* 2017, 123, 3080–3087. [CrossRef]
152. Otake, E.; Sakuma, S.; Torii, K.; Maeda, A.; Ohi, H.; Yano, S.; Morita, A. Effect and mechanism of a new photodynamic therapy with glycoconjugated fullerene. *Photochem. Photobiol.* 2010, 86, 1356–1363. [CrossRef] [PubMed]

153. Hong, S.S.; Zhang, M.X.; Zhang, M.; Yu, Y.; Chen, J.; Zhang, X.Y.; Xu, C.J. Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-alpha silencing and antitumor activity against ovarian cancer. *Drug Deliv.* 2018, 25, 576–584. [CrossRef] [PubMed]

154. Frankel, A.E.; Zucker, S.L.; Mankin, A.A.; Grable, M.; Mitchell, K.; Lee, Y.J.; Neville, D.M.; Woo, J.H. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. *Curr. Drug Targets* 2009, 10, 104–109. [CrossRef] [PubMed]

155. Kantarjian, H.M.; Lioure, B.; Kim, S.K.; Atallah, E.; Leguay, T.; Kelly, K.; Marolleau, J.P.; Escoffre-Barbe, M.; Thomas, X.G.; Cortes, J.; et al. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. *Clin. Lymphoma Myeloma Leuk.* 2016, 16, 139–145. [CrossRef] [PubMed]

156. Ogura, M.; Tobinai, K.; Hatake, K.; Davies, A.; Crump, M.; Ananthakrishnan, R.; Ishibashi, T.; Paccagnella, M.L.; Boni, J.; Vandendries, E.; et al. Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. *Clin. Cancer Res.* 2016, 22, 4807–4816. [CrossRef] [PubMed]

157. Wayne, A.S.; Shah, N.N.; Bhojwani, D.; Silverman, L.B.; Whitlock, J.A.; Stetler-Stevenson, M.; Sun, W.; Liang, M.; Yang, J.; Kreitman, R.J.; et al. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. *Blood* 2017, 129, 1620–1627. [CrossRef]

158. Kreitman, R.J.; Stetler-Stevenson, M.; Jaffe, E.S.; Conlon, K.C.; Steinberg, S.M.; Wilson, W.; Waldmann, T.A.; Pastan, I. Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. *Clin. Cancer Res.* 2016, 22, 310–318. [CrossRef] [PubMed]

159. Zinzani, P.L.; Pellegrini, C.; Chiappella, A.; Di Rocco, A.; Salvi, F.; Cabras, M.G.; Argnani, L.; Stefoni, V. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: Results from a phase 2 clinical trial. *Blood* 2017, 129, 2328–2330. [CrossRef]

160. Sherbenou, D.W.; Aftab, B.T.; Su, Y.; Behrens, C.R.; Wiita, A.; Logan, A.C.; Acosta-Alvey, D.; Hann, B.C.; Walter, P.; Shuman, M.A.; et al. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. *J. Clin. Investig.* 2016, 126, 4640–4653. [CrossRef]

161. Berdeja, J.G.; Ailawadhi, S.; Weitman, S.D.; Zildjian, S.; O'Leary, J.J.; O'Keeffe, J.; Guild, R.; Whiteman, K.; Chanan-Khan, A. Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). *Clin. Oncol.* 2011, 29, 8013. [CrossRef]

162. Jeffrey, S.C.; Burke, P.J.; Lyon, R.P.; Meyer, D.W.; Sussman, D.; Anderson, M.; Hunter, J.H.; Leiske, C.L.; Miyamoto, J.B.; Nicholas, N.D.; et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. *Bioconjugate Chem.* 2013, 24, 1256–1263. [CrossRef] [PubMed]

163. Sapra, P.; Stein, R.; Pickett, J.; Qu, Z.; Govindan, S.V.; Cardillo, T.M.; Hansen, H.J.; Horak, I.D.; Griffiths, G.L.; Goldenberg, D.M. Anti-CD74 antibody-drug conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. *Clin. Cancer Res.* 2005, 11, 5257–5264. [CrossRef] [PubMed]

164. Tai, Y.T.; Mayes, P.A.; Acharya, C.; Zhong, M.Y.; Cea, M.; Cagnetta, A.; Craigen, J.; Yates, J.; Gliddon, L.; Fieles, W.; et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. *Blood* 2014, 123, 3128–3138. [CrossRef] [PubMed]

165. Salomon, D.S.; Brandt, R.; Cardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit. Rev. Oncol. Hematol.* 1995, 19, 183–232. [CrossRef]

166. Ocan, A.; Pandiella, A. Targeting HER receptors in cancer. *Curr. Pharm. Des.* 2013, 19, 808–817. [CrossRef] [PubMed]

167. Polonovski, O.L.; Lebedenko, E.N.; Deyev, S.M. ERBB oncogene proteins as targets for monoclonal antibodies. *Biochem. Biokhim.* 2012, 77, 227–245. [CrossRef] [PubMed]

168. Ballantyne, A.; Dhillon, S. Trastuzumab emtansine: First global approval. *Drugs* 2013, 73, 755–765. [CrossRef] [PubMed]
169. Yang, W.; Barth, R.F.; Wu, G.; Huo, T.; Tjarks, W.; Ciesielski, M.; Fenstermaker, R.A.; Ross, B.D.; Wikstrand, C.J.; Riley, K.J.; et al. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors. J. Neuro-Oncol. 2009, 95, 355–365. [CrossRef]

170. Wu, G.; Yang, W.; Barth, R.F.; Kawabata, S.; Swindall, M.; Bandypadhyaya, A.K.; Tjarks, W.; Khorosandi, B.; Blue, T.E.; Ferketic, A.K.; et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 2007, 13, 1260–1268. [CrossRef] [PubMed]

171. Pai-Scherf, L.H.; Villa, J.; Pearson, D.; Watson, T.; Liu, E.; Willingham, M.C.; Pastan, I. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin. Cancer Res. 1999, 5, 2311–2315. [PubMed]

172. Azemar, M.; Djahansouzi, S.; Jager, E.; Solbach, C.; Schmidt, M.; Maurer, A.B.; Mross, K.; Unger, C.; von Minckwitz, G.; Dell, P.; et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res. Treat. 2003, 82, 155–164. [CrossRef] [PubMed]

173. Sampson, J.H.; Akabani, G.; Archer, G.E.; Berger, M.S.; Coleman, R.E.; Friedman, A.H.; Friedman, H.S.; Greer, K.; Herndon, J.E.; Kunwar, S.; et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncol. 2008, 10, 320–329. [CrossRef]

174. Chandramohan, V.; Pegram, C.N.; Piao, H.; Szafranski, S.E.; Kuan, C.T.; Pastan, I.H.; Bigner, D.D. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. Appl. Microbiol. Biotechnol. 2017, 101, 2747–2766. [CrossRef]

175. Mahmud, H.; Dalken, B.; Wels, W.S. Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor. Mol. Cancer Ther. 2009, 8, 1526–1535. [CrossRef] [PubMed]

176. Serebrovskaya, E.O.; Edelweiss, E.F.; Stremovskiy, O.A.; Lukyanov, K.A.; Chudakov, D.M.; Deyev, S.M. Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein. Proc. Natl. Acad. Sci. USA 2009, 106, 9221–9225. [CrossRef]

177. Wang, F.; Ren, J.; Qiu, X.C.; Wang, L.F.; Zhu, Q.; Zhang, Y.Q.; Huan, Y.; Meng, Y.L.; Yao, L.B.; Chen, S.Y.; et al. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23scFv-TD-tBID protein containing a furin cleavage sequence. Clin. Cancer Res. 2010, 16, 2284–2294. [CrossRef]

178. Mironova, K.E.; Proshkina, G.M.; Ryabova, A.V.; Stremovskiy, O.A.; Lukyanov, S.A.; Petrov, R.V.; Deyev, S.M. Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro. Theranostics 2013, 3, 831–840. [CrossRef] [PubMed]

179. Babar, N.; Abdul-Hai, A.; Mancini, M.; Lindzen, M.; Lavi, S.; Leitner, O.; Mounier, L.; Chentouf, M.; Dunoyer, S.; Ghosh, M.; et al. Examination of HER3 targeting in cancer using monoclonal antibodies. Proc. Natl. Acad. Sci. USA 2015, 112, 839–844. [CrossRef]

180. Sadat, S.M.; Saeidnia, S.; Nazaralli, A.J.; Haddadi, A. Nano-pharmaceutical formulations for targeted drug delivery against HER2 in breast cancer. Curr. Cancer Drug Targets 2015, 15, 71–86. [CrossRef]

181. Meng, J.; Liu, Y.; Gao, S.; Lin, S.; Gu, X.; Pomper, M.G.; Wang, P.C.; Shan, L. A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression. Cancer Biol. Ther. 2015, 16, 1764–1774. [CrossRef] [PubMed]

182. Niesen, J.; Hehmann-Titt, G.; Woitok, M.; Fendel, R.; Barth, S.; Fischer, R.; Stein, C. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor. Cancer Lett. 2016, 374, 229–240. [CrossRef]

183. Sokolova, E.; Guryev, E.; Yudintsev, A.; Vodeneev, V.; Deyev, S.; Balalaev, I. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis. Oncotarget 2017, 8, 22048–22058. [CrossRef] [PubMed]

184. Deng, C.; Xiong, J.; Gu, X.; Chen, X.; Wu, S.; Wang, Z.; Wang, D.; Tu, J.; Xie, J. Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro. Oncotarget 2017, 8, 38568–38580. [CrossRef]

185. Proshkina, G.M.; Kiseleva, D.V.; Shilova, O.N.; Ryabova, A.V.; Shramova, E.I.; Stremovskiy, O.A.; Deyev, S.M. [Bifunctional Toxin DARP-LoPE Based on the HER2-Specific Innovative Module of a Non-Immunoglobulin Scaffold as a Promising Agent for Theranostics]. Mol. Biol. 2017, 51, 997–1007. [CrossRef]
186. Prager, G.W.; Poettler, M.; Unseld, M.; Zielinski, C.C. Angiogenesis in cancer: Anti-VEGF escape mechanisms. *Transl. Lung Cancer Res.* **2012**, *1*, 14–25. [CrossRef] [PubMed]

187. Fokong, S.; Theek, B.; Wu, Z.; Koczera, P.; Appold, L.; Jorge, S.; Resch-Genger, U.; van Zandvoort, M.; Storm, G.; Kiessling, F.; et al. Image-guided, targeted and triggered drug delivery to tumors using polymer-based microbubbles. *J. Contrull. Release* **2012**, *163*, 75–81. [CrossRef] [PubMed]

188. Goel, S.; Chen, F.; Hong, H.; Valdivinos, H.F.; Hernandez, R.; Shi, S.; Barnhart, T.E.; Cai, W. VEGF(1)(2)(1)-conjugated mesoporous silica nanoparticle: A tumor targetted drug delivery system. *ACS Appl. Mater. Interfaces* **2014**, *6*, 21677–21685. [CrossRef] [PubMed]

189. Dvorak, H.F. Tumor Stroma, Tumor Blood Vessels, and Angiogenesis Therapy. *Cancer J.* **2015**, *21*, 237–243. [CrossRef] [PubMed]

190. Qian, Z.M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. *Pharmacol. Rev.* **2002**, *54*, 561–587. [CrossRef] [PubMed]

191. Tortorella, S.; Karagiannis, T.C. Transferrin receptor-mediated endocytosis: A useful target for cancer therapy. *J. Membr. Biol.* **2014**, *247*, 291–307. [CrossRef] [PubMed]

192. Tortorella, S.; Karagiannis, T.C. The significance of transferrin receptors in oncology: The development of functional nano-based drug delivery systems. *Curr. Drug Deliv.* **2014**, *11*, 427–443. [CrossRef] [PubMed]

193. Nogueira-Librelotto, D.R.; Codevilla, C.F.; Farooqi, A.; Rolim, C.M. Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy. *Curr. Pharm. Des.* **2017**, *23*, 454–466. [CrossRef] [PubMed]

194. Chen, S.; Zhao, X.; Chen, J.; Chen, J.; Kuznetsova, L.; Wong, S.S.; Ojima, I. Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. *Bioconjugate Chem.* **2010**, *21*, 979–987. [CrossRef] [PubMed]

195. Maiti, S.; Paira, P. Biotin conjugated organic molecules and proteins for cancer therapy: A review. *Eur. J. Med. Chem.* **2018**, *145*, 206–224. [CrossRef] [PubMed]

196. Carron, P.M.; Crowley, A.; O’Shea, D.; McCann, M.; Howe, O.; Hunt, M.; Devereux, M. Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry. *Curr. Med. Chem.* **2018**, *25*, 2673–2708. [CrossRef] [PubMed]

197. Subia, B.; Chandra, S.; Talukdar, S.; Kundu, S.C. Folate conjugated silk fibroin nanocarriers for targeted drug delivery. *Integr. Biol.* **2014**, *6*, 203–214. [CrossRef] [PubMed]

198. Niemela, E.; Desai, D.; Nkizinkiko, Y.; Eriksson, J.E.; Rosenholm, J.M. Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celestrol enables targeted induction of apoptosis in cancer cells. *Eur. J. Pharm. Biopharm.* **2015**, *96*, 11–21. [CrossRef] [PubMed]

199. Eroglu, M.S.; Oner, E.T.; Mutlu, E.C.; Bostan, M.S. Sugar Based Biopolymers in Nanomedicine; New Emerging Era for Cancer Imaging and Therapy. *Curr. Top. Med. Chem.* **2015**, *17*, 1507–1520. [CrossRef] [PubMed]

200. Tanasova, M.; Begoyan, V.V.; Weselinski, L.J. Targeting Sugar Uptake and Metabolism for Cancer Identification and Therapy: An Overview. *Curr. Top. Med. Chem.* **2018**, *18*, 467–483. [CrossRef]

201. Mittal, N.K.; Bhattacharjee, H.; Mandal, B.; Balabathula, P.; Thoma, L.A.; Wood, G.C. Targeted liposomal drug delivery systems for the treatment of B cell malignancies. *J. Drug Target.* **2014**, *22*, 372–386. [CrossRef] [PubMed]

202. Stephenson, R.; Singh, A. Drug discovery and therapeutic delivery for the treatment of B and T cell tumors. *Adv. Drug Deliv. Rev.* **2017**, *114*, 285–300. [CrossRef] [PubMed]

203. Wolska-Washer, A.; Robak, P.; Smolewski, P.; Robak, T. Emerging antibody-drug conjugates for treating lymphoid malignancies. *Expert Opin. Emerg. Drugs* **2017**, *22*, 259–273. [CrossRef] [PubMed]

204. Wang, B.; Lv, L.; Wang, Z.; Zhao, Y.; Wu, L.; Fang, X.; Xu, Q.; Xin, H. Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor alpha2-mediated endocytosis. *Biomaterials* **2014**, *35*, 5897–5907. [CrossRef] [PubMed]

205. Showalter, S.L.; Huang, Y.H.; Witkiewicz, A.; Costantino, C.L.; Yeo, C.J.; Green, J.J.; Langer, R.; Anderson, D.G.; Sawicki, J.A.; Brody, J.R. Nanoparticulate delivery of diphertheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. *Cancer Biol. Ther.* **2008**, *7*, 1584–1590. [CrossRef] [PubMed]

206. Pastan, I.; Hassan, R. Discovery of mesothelin and exploiting it as a target for immunotherapy. *Cancer Res.* **2014**, *74*, 2907–2912. [CrossRef] [PubMed]
208. Barve, A.; Jin, W.; Cheng, K. Prostate cancer relevant antigens and enzymes for targeted drug delivery. J. Controll. Release 2014, 187, 118–132. [CrossRef] [PubMed]

209. DiPippo, V.A.; Olson, W.C.; Nguyen, H.M.; Brown, L.G.; Vessella, R.L.; Corey, E. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. Prostate 2015, 75, 303–313. [CrossRef] [PubMed]

210. Duffy, C.V.; David, L.; Crouzier, T. Covalently-crosslinked mucin biopolymer hydrogels for sustained drug delivery. Acta Biomater. 2015, 20, 51–59. [CrossRef]

211. Nabavinia, M.S.; Gholoobi, A.; Charbgoo, F.; Nabavinia, M.; Ramezani, M.; Abnous, K. Anti-MUC1 aptamer: A potential opportunity for cancer treatment. Med. Res. Rev. 2017, 37, 1518–1539. [CrossRef] [PubMed]

212. De Oliveira Figueirao, E.; Albuquerque da Cunha, C.R.; Albuquerque, P.B.S.; de Paula, R.A.; Aranda-Souza, M.A.; Alves, M.S.; Zagmignan, A.; Carneiro-da-Cunha, M.G.; Nascimento da Silva, L.C.; Dos Santos Correia, M.T. Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents. Curr. Med. Chem. 2017, 24, 3667–3680. [CrossRef] [PubMed]

213. Belli, C.; Trapani, D.; Viale, G.; D’Amico, P.; Duso, B.A.; Della Vigna, P.; Orsi, F.; Curigliano, G. Targeting the microenvironment in solid tumors. Cancer Treat. Rev. 2018, 65, 22–32. [CrossRef] [PubMed]

214. Von Hoff, D.D.; Ervin, T.; Arena, F.P.; Chioran, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S.A.; Ma, W.W.; Saleh, M.N.; et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N. Engl. J. Med. 2013, 369, 1691–1703. [CrossRef] [PubMed]

215. Morris, J.C.; Tan, A.R.; Olenczi, T.E.; Shapiro, G.J.; Reiss, M.; Hsu, F.J.; Berzofsky, J.A.; Lawrence, D.P. Phase I study of GC1008 (fresolimumab): A human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 2014, 9, e90353. [CrossRef] [PubMed]

216. Cassier, P.A.; Italiano, A.; Gomez-Roca, C.A.; Le Tournear, C.; Toulmonde, M.; Cannarile, M.A.; Ries, C.; Brillouet, A.; Muller, C.; Jegg, A.M.; et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: A dose-escalation and dose-expansion phase 1 study. Lancet. Oncol. 2015, 16, 949–956. [CrossRef]

217. Bennouna, J.; Sastre, J.; Arnold, D.; Osterlund, P.; Greil, R.; Van Cutsem, E.; von Moos, R.; Vieitez, J.M.; Bouche, O.; Borg, C.; et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet. Oncol. 2013, 14, 29–37. [CrossRef]

218. Van Cutsem, E.; Tabernero, J.; Lakomy, R.; Prausova, J.; Macarulla, T.; Ruff, P.; van Hazel, G.A.; Moiseyenko, V.; Ferry, D.; et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012, 30, 3499–3506. [CrossRef]

219. Egorova, A.; Shubina, A.; Sokolov, D.; Selkov, S.; Baranov, V.; Kiselev, A. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery. Int. J. Pharm. 2016, 515, 431–440. [CrossRef]

220. Topalian, S.L. Targeting Immune Checkpoints in Cancer Therapy. JAMA 2017, 318, 1647–1648. [CrossRef]

221. Khawar, I.A.; Kim, J.H.; Kuh, H.J. Improving drug delivery to solid tumors: Priming the tumor microenvironment. J. Controll. Release 2015, 201, 78–89. [CrossRef] [PubMed]

222. Yang, S.; Gao, H. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacol. Res. 2017, 126, 97–108. [CrossRef] [PubMed]

223. Fu, X.; Yang, Y.; Li, X.; Lai, H.; Huang, Y.; He, L.; Zheng, W.; Chen, T. RGD peptide-conjugated selenium nanoparticles: Antiangiogenesis by suppressing VEGF-VEGFR2-ERK/AKT pathway. Nanomedicine 2016, 12, 1627–1639. [CrossRef] [PubMed]

224. Li, X.; Wu, M.; Pan, L.; Shi, J. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor. Int. J. Nanomed. 2016, 11, 93–105. [CrossRef] [PubMed]

225. Overington, J.P.; Al-Lazikani, B.; Hopkins, A.L. How many drug targets are there? Nat. Rev. Drug Discov. 2006, 5, 993–996. [CrossRef]

226. Vhora, I.; Patil, S.; Bhatt, P.; Gandhi, R.; Baradia, D.; Misra, A. Receptor-targeted drug delivery: Current perspective and challenges. Ther. Deliv. 2014, 5, 1007–1024. [CrossRef]

227. Deyev, S.M.; Lebedenko, E.N. Modern Technologies for Creating Synthetic Antibodies for Clinical application. Acta Nat. 2009, 1, 32–50.
228. Pietersz, G.A.; Wang, X.; Yap, M.L.; Lim, B.; Peter, K. Therapeutic targeting in nanomedicine: The future lies in recombinant antibodies. *Nanomedicine* 2017, 12, 1873–1889. [CrossRef]

229. Hurwitz, E.; Maron, R.; Arnon, R.; Sela, M. Fab dimers of antitumor immunoglobulins as covalent carriers of daunomycin. *Cancer Biochem. Biophys.* 1976, 1, 197–202.

230. Bird, R.E.; Hardman, K.D.; Jacobson, J.W.; Johnson, S.; Kaufman, B.M.; Lee, S.M.; Lee, T.; Pope, S.H.; Riordan, G.S.; Whitlow, M. Single-chain antigen-binding proteins. *Science* 1988, 242, 423–426. [CrossRef]

231. Huston, J.S.; Levinson, D.; Mudgett-Hunter, M.; Tai, M.S.; Novotny, J.; Margolies, M.N.; Ridge, R.J.; Brucoleri, R.E.; Haber, E.; Crea, R.; et al. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. *Proc. Natl. Acad. Sci. USA* 1988, 85, 5879–5883. [CrossRef]

232. Brinkmann, U.; Reiter, Y.; Jung, S.H.; Lee, B.; Pastan, I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. *Proc. Natl. Acad. Sci. USA* 1993, 90, 7538–7542. [CrossRef]

233. Brinkmann, U.; Reiter, Y.; Paust, I. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: Disulfide-stabilized Fv immunotoxins. *Clin. Cancer Res.* 1996, 2, 245–252.

234. Hamers-Casterman, C.; Atarhouch, T.; Muyldermans, S.; Robinson, G.; Hamers, C.; Songa, E.B.; Reiter, Y.; Pastan, I. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: Disulfide-stabilized Fv immunotoxins. *Clin. Cancer Res.* 1996, 2, 245–252.

235. Nelson, A.L. Antibody fragments: Hope and hype. *mAbs* 2010, 2, 77–83. [CrossRef] [PubMed]

236. Shan, L.; Liu, Y.; Wang, P. Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies. *J. Basic Clin. Med.* 2013, 2, 1–6.

237. Alibakhshi, A.; Abarghooi Kahaki, F.; Ahangarzadeh, S.; Yaghoobi, H.; Yarian, F.; Arezumand, R.; Ranjbari, J.; Petrovskaia, L.E.; Shingarova, L.N.; Dolgikh, D.A.; Kirpichnikov, M.P. [Alternative scaffold proteins]. *Cancers* 2017, 12, 1873–1889. [CrossRef]

238. Bird, R.E.; Hardman, K.D.; Jacobson, J.W.; Johnson, S.; Kaufman, B.M.; Lee, S.M.; Lee, T.; Pope, S.H.; Riordan, G.S.; Whitlow, M. Single-chain antigen-binding proteins. *Science* 1988, 242, 423–426. [CrossRef]

239. Kim, A.; Sinha, B.; Seligmann, D.; Feng, J.; Trumbauer, M.; Abney, S.; Pastan, I.; Pastan, I. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: Disulfide-stabilized Fv immunotoxins. *Clin. Cancer Res.* 1996, 2, 245–252.

240. Hollevoet, K.; Mason-Osann, E.; Liu, X.F.; Imhof-Jung, S.; Niederfellner, G.; Pastan, I. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. *Mol. Cancer Ther.* 2017, 16, 2040–2049. [CrossRef] [PubMed]

241. Yu, Y.; Li, J.; Zhu, X.; Tang, X.; Yao, Y.; Sun, X.; Huang, Y.; Tian, F.; Liu, X.; Yang, L. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. *Int. J. Nanomed.* 2017, 12, 1969–1983. [CrossRef] [PubMed]

242. D’Hollander, A.; Jans, H.; Verstraete, C.; Massa, S.; Devoogdt, N.; Stakenborg, T.; Muyldermans, S.; Lagae, L.; Himmelreich, U. Limiting the protein corona: A successful strategy for in vivo active targeting of anti-HER2 nanobody-functionalized nanostars. *Biomaterials* 2017, 123, 15–23. [CrossRef] [PubMed]

243. Petrovskaia, L.E.; Shingarova, L.N.; Dolgikh, D.A.; Kirpichnikov, M.P. [Alternative scaffold proteins]. *Bioorg. Khim.* 2011, 37, 581–591. [CrossRef] [PubMed]

244. Vazquez-Lombardi, A.; Han, T.G.; Zimmermann, C.; Lowe, D.; Jermutus, L.; Christ, D. Challenges and opportunities for non-antibody scaffold drugs. *Drug Discov. Today* 2015, 20, 1271–1283. [CrossRef] [PubMed]

245. Bedford, R.; Tiede, C.; Hughes, R.; Curd, A.; McPherson, M.J.; Peckham, M.; Tomlinson, D.C. Alternative reagents to antibodies in imaging applications. *Biophys. Res.* 2017, 9, 299–308. [CrossRef] [PubMed]

246. Simeon, R.; Chen, Z. In vitro-engineered non-antibody protein therapeutics. *Protein Cell* 2018, 9, 3–14. [CrossRef] [PubMed]

247. Tolcher, A.W.; Sweeney, C.J.; Papadopoulos, K.; Patnaik, A.; Chiorean, E.G.; Mita, A.C.; Sankhala, K.; Furfine, E.; Gokemeijer, J.; Iacono, L.; et al. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. *Clin. Cancer Res.* 2011, 17, 363–371. [CrossRef]
248. Graf, N.; Mokhtari, T.E.; Papayannopoulos, I.A.; Lippard, S.J. Platinum (IV)-chlorotoxin (CTX) conjugates for targeting cancer cells. *J. Inorg. Biochem.* 2012, 110, 58–63. [CrossRef]

249. Cox, N.; Kintzing, J.R.; Smith, M.; Grant, G.A.; Cochrane, J.R. Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. *Angew. Chem. Int. Ed.* 2016, 55, 9894–9897. [CrossRef]

250. Wuellner, U.; Klupsch, K.; Buller, F.; Attinger-Toller, I.; Santimaria, R.; Zbinden, I.; Henne, P.; Grabulovski, D.; Bertschinger, J.; Brack, S. Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity. *Antibodies* 2015, 4, 426–440. [CrossRef]

251. Klupsch, K.; Baeriswyl, V.; Scholz, R.; Dannenberg, J.; Santimaria, R.; Senn, D.; Kage, E.; Zumsteg, A.; Attinger-Toller, I.; von der Bey, U.; et al. COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia. *Leukemia* 2018. [CrossRef] [PubMed]

252. Albrecht, V.; Richter, A.; Pfeiffer, S.; Gebauer, M.; Lindner, S.; Gieser, E.; Schuller, U.; Schichor, C.; Gildehaus, F.J.; Bartenstein, P.; et al. Anticalins directed against the fibronectin extra domain B as diagnostic tracers for glioblastomas. *Int. J. Cancer* 2016, 138, 1269–1280. [CrossRef] [PubMed]

253. De Souza, J.G.; Morais, K.L.; Angles-Cano, E.; Boufleur, P.; de Mello, E.S.; Maria, D.A.; Origassa, C.S.; de Campos Zampolli, H.; Camara, N.O.; Berra, C.M.; et al. Promising pharmacological profile of a Kunirtz-type inhibitor in murine renal cell carcinoma model. *Oncotarget* 2016, 7, 62255–62266. [CrossRef] [PubMed]

254. Singh, Y.; Durca Rao Viswanadham, K.K.; Kumar Jajoriya, A.; Meher, J.G.; Raval, K.; Jaiswal, S.; Dewangan, J.; Bora, H.K.; Rath, S.K.; Lal, J.; et al. Click Biotinylation of PLGA Template for Biotin Receptor Oriented Delivery of Doxorubicin Hydrochloride in 4T1 Cell-Induced Breast Cancer. *Mol. Pharm.* 2017, 14, 2749–2765. [CrossRef]

255. Dixit, S.; Novak, T.; Miller, K.; Zhu, Y.; Kenney, M.E.; Broome, A.M. Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. *Nanoscale* 2015, 7, 1782–1790. [CrossRef] [PubMed]

256. Wang, F.; Li, Y.; Shen, Y.; Wang, A.; Wang, S.; Xie, T. The functions and applications of RGD in tumor therapy and tissue engineering. *Int. J. Mol. Sci.* 2013, 14, 13447–13462. [CrossRef] [PubMed]

257. Pierschbacher, M.D.; Ruoslahti, E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. *Nature* 1984, 309, 30–33. [CrossRef] [PubMed]

258. Sugahara, K.N.; Teesalu, T.; Karmali, P.P.; Kotamraju, V.R.; Agemy, L.; Girard, O.M.; Hanahan, D.; Liu, X.; Jiang, J.; Ji, Y.; Lu, J.; Chan, R.; Meng, H. Targeted drug delivery using iRGD peptide for solid cancer treatments. *Nanoscale* 2016, 8, 1601–1618. [CrossRef] [PubMed]

259. Roxin, A.; Zheng, G. Flexible or fixed: A comparative review of linear and cyclic cancer-targeting peptides. *Future Med. Chem.* 2012, 4, 1601–1618. [CrossRef] [PubMed]

260. Liu, X.; Jiang, J.; Ji, Y.; Lu, J.; Chan, R.; Meng, H. Targeted drug delivery using iRGD peptide for solid cancer treatment. *Mol. Syst. Des. Eng.* 2017, 2, 370–379. [CrossRef] [PubMed]

261. Singh, Y.; Durca Rao Viswanadham, K.K.; Kumar Jajoriya, A.; Meher, J.G.; Raval, K.; Jaiswal, S.; Dewangan, J.; Bora, H.K.; Rath, S.K.; Lal, J.; et al. Click Biotinylation of PLGA Template for Biotin Receptor Oriented Delivery of Doxorubicin Hydrochloride in 4T1 Cell-Induced Breast Cancer. *Mol. Pharm.* 2017, 14, 2749–2765. [CrossRef]

262. Zhang, J.; Hu, J.; Chan, H.F.; Skibba, M.; Liang, G.; Chen, M. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. *Nanomedicine* 2016, 12, 1303–1311. [CrossRef] [PubMed]

263. Zuo, H.D.; Yao, W.W.; Chen, T.W.; Zhu, J.; Zhang, J.J.; Pu, Y.; Liu, G.; Zhang, X.M. The effect of superparamagnetic iron oxide with iRGD peptide on the labeling of pancreatic cancer cells in vitro: A preliminary study. *BioMed Res. Int.* 2014, 2014, 852352. [CrossRef]

264. DeBin, J.A.; Maggio, J.E.; Strichartz, G.R. Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. *Am. J. Physiol.* 1993, 264, C361–C369. [CrossRef] [PubMed]

265. Sorocenau, L.; Gillespie, Y.; Khazaeli, M.B.; Sontheimer, H. Use of chlorotoxin for targeting of primary brain tumors. *Cancer Res.* 1998, 58, 4871–4879. [PubMed]

266. Arzamasov, A.A.; Vassilevski, A.A.; Grishin, E.V. Chlorotoxin and related peptides: Short insect toxins from scorpion venom. *Russ. J. Bioorg. Chem.* 2014, 40, 359–369. [CrossRef]

267. Ojeda, P.G.; Wang, C.K.; Craig, D.J. Chlorotoxin: Structure, activity, and potential uses in cancer therapy. *Biopolymers* 2016, 106, 25–36. [CrossRef] [PubMed]
268. Gautam, A.; Kapoor, P.; Chaudhary, K.; Kumar, R.; Raghava, G.P. Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics. Curr. Med. Chem. 2014, 21, 2367–2391. [CrossRef] [PubMed]

269. Tashima, T. Effective cancer therapy based on selective drug delivery into cells across their membrane using receptor-mediated endocytosis. Bioorg. Med. Chem. Lett. 2018, 28, 3015–3024. [CrossRef] [PubMed]

270. Copolovici, D.M.; Langel, K.; Eriste, E.; Langel, U. Cell-penetrating peptides: Design, synthesis, and applications. ACS Nano 2014, 8, 1972–1994. [CrossRef] [PubMed]

271. Wang, W.; Abbad, S.; Zhang, Z.; Wang, S.; Zhou, J.; Lv, H. Cell-penetrating Peptides for Cancer-targeting Therapy and Imaging. Curr. Cancer Drug Targets 2015, 15, 337–351. [CrossRef] [PubMed]

272. Penon, O.; Marin, M.J.; Russell, D.A.; Perez-Garcia, L. Water soluble, multifunctional antibody-porphyrin gold nanoparticles for targeted photodynamic therapy. J. Colloid Interface Sci. 2017, 496, 100–110. [CrossRef] [PubMed]

273. Obaid, G.; Chambrier, I.; Cook, M.J.; Russell, D.A. Cancer targeting with biomolecules: A comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles. Photochem. Photobiol. Sci. 2015, 14, 737–747. [CrossRef] [PubMed]

274. Basel, M.T.; Shrestha, T.B.; Bossmann, S.H.; Troyer, D.L. Cells as delivery vehicles for cancer therapeutics. Ther. Deliv. 2014, 5, 555–567. [CrossRef] [PubMed]

275. Huang, B.; Abraham, W.D.; Zheng, Y.; Bustamante Lopez, S.C.; Luo, S.S.; Irvine, D.J. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci. Transl. Med. 2015, 7, 291ra294. [CrossRef] [PubMed]

276. Stephan, M.T.; Moon, J.J.; Um, S.H.; Bershteyn, A.; Irvine, D.J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 2010, 16, 1035–1041. [CrossRef] [PubMed]

277. De Palma, M.; Mazzieri, R.; Politi, L.S.; Pucci, F.; Zonari, E.; Sitia, G.; Mazzoleni, S.; Moi, D.; Venneri, M.A.; Indraccolo, S.; et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008, 14, 299–311. [CrossRef] [PubMed]

278. Basel, M.T.; Balivada, S.; Wang, H.; Shrestha, T.B.; Sea, G.M.; Pyle, M.; Abayaweera, G.; Dani, R.; Koper, O.B.; Tamura, M.; et al. Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model. Int. J. Nanomed. 2012, 7, 297–306. [CrossRef] [PubMed]

279. Xue, J.; Zhao, Z.; Zhang, L.; Xue, L.; Shen, S.; Wen, Y.; Wei, Z.; Wang, L.; Kong, L.; Sun, H.; et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat. Nanotechnol. 2017, 12, 692–700. [CrossRef] [PubMed]

280. Matsu, M.; Shimizu, Y.; Kodera, Y.; Kondo, E.; Ikehara, Y.; Nakamichi, H. Targeted delivery of oligomannose-coated liposome to the omental micrometastasis by peritoneal macrophages from patients with gastric cancer. Cancer Sci. 2010, 101, 1670–1677. [CrossRef]

281. Choi, J.; Kim, H.Y.; Ju, E.J.; Jung, J.; Park, J.; Chung, H.K.; Lee, J.S.; Lee, J.S.; Park, H.J.; Song, S.Y.; et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials 2012, 33, 4195–4203. [CrossRef] [PubMed]

282. Roger, M.; Clavreul, A.; Venier-Julienne, M.C.; Passirani, C.; Sindji, L.; Schiller, P.; Montero-Menei, C.; Menei, P. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 2010, 31, 8393–8401. [CrossRef] [PubMed]

283. Sadhukha, T.; O’Brien, T.D.; Prabha, S. Nano-engineered mesenchymal stem cells as targeted therapeutic carriers. J. Control. Release 2014, 196, 243–251. [CrossRef] [PubMed]

284. Aboody, K.S.; Brown, A.; Rainov, N.G.; Bower, K.A.; Liu, S.; Yang, W.; Small, J.E.; Herrlinger, U.; Ourednik, V.; Black, P.M.; et al. Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc. Natl. Acad. Sci. USA 2000, 97, 12846–12851. [CrossRef] [PubMed]

285. Schnarr, K.; Mooney, R.; Weng, Y.; Zhao, D.; Garcia, E.; Armstrong, B.; Annala, A.J.; Kim, S.U.; Aboody, K.S.; Berlin, J.M. Gold nanoparticle-loaded neural stem cells for photothermal ablation of cancer. Adv. Healthc. Mater. 2013, 2, 976–982. [CrossRef]

286. Studeny, M.; Marin, F.C.; Champlin, R.E.; Zompetta, C.; Fieller, I.J.; Andreff, M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002, 62, 3603–3608. [CrossRef] [PubMed]

287. Komarova, S.; Kawakami, Y.; Stoff-Khallili, M.A.; Curry, D.T.; Pereboeva, L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. 2006, 5, 755–766. [CrossRef] [PubMed]
288. Roger, M.; Clavreul, A.; Venier-Julienne, M.C.; Passirani, C.; Montero-Menei, C.; Menei, P. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. *Biomaterials* 2011, 32, 2106–2116. [CrossRef]

289. Riviere, I.; Sadelain, M. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. *Mol. Ther.* 2017, 25, 1117–1124. [CrossRef]

290. Agrahari, V.; Agrahari, V.; Mitra, A.K. Next generation drug delivery: Circulatory cells-mediated nanotherapeutic approaches. *Expert Opin. Drug Deliv.* 2017, 14, 285–289. [CrossRef]

291. Jokerst, J.V.; Lobovkina, T.; Zare, R.N.; Gambhir, S.S. Nanoparticle PEGylation for imaging and therapy. *Nanomedicine* 2011, 6, 715–728. [CrossRef]

292. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U.S. Poly (ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives. *Angew. Chem. Int. Ed.* 2010, 49, 6288–6308. [CrossRef] [PubMed]

293. Verhoef, J.J.F.; Anchordoquy, T.J. Questioning the Use of PEGylation for Drug Delivery. *Drug Deliv. Transl. Res.* 2013, 3, 499–503. [CrossRef] [PubMed]

294. Zhang, P.; Sun, F.; Liu, S.; Jiang, S. Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation. *J. Control. Release* 2016, 244, 184–193. [CrossRef]

295. Muller, J.; Bauer, K.N.; Prozeller, D.; Simon, J.; Mailander, V.; Wurm, F.R.; Winzen, S.; Landfester, K. Coating nanoparticles with tunable surfactants facilitates control over the protein corona. *Biomaterials* 2017, 115, 1–8. [CrossRef] [PubMed]

296. Safavї-Sohi, R.; Maghari, S.; Raoufi, M.; Jalali, S.A.; Hajipour, M.J.; Ghassempour, A.; Mahmoudi, M. Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors. *ACS Appl. Mater. Interfaces* 2016, 8, 22808–22818. [CrossRef]

297. Oh, J.Y.; Kim, H.S.; Palanikumar, L.; Go, E.M.; Jana, B.; Park, S.A.; Kim, H.Y.; Kim, K.; Seo, J.K.; Kwak, S.K.; et al. Cloaking nanoparticles with protein corona shield for targeted drug delivery. *Nat. Commun.* 2018, 9, 4548. [CrossRef]

298. Mailänder, V.; Simon, J.; Müller, L.K.; Kokkinopoulou, M.; Lieberwirth, I.; Morsbach, S.; Landfester, K. Exploiting the biomolecular corona: Pre-coating of nanoparticles enables controlled cellular interactions. *Nanoscale* 2018, 10, 10731–10739.

299. Jain, R.K. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. *Science* 2005, 307, 58–62. [CrossRef]

300. Goel, S.; Duda, D.G.; Xu, L.; Munn, L.L.; Boucher, Y.; Fukumura, D.; Jain, R.K. Normalization of the vasculature for treatment of cancer and other diseases. *Physiol. Rev.* 2011, 91, 1071–1121. [CrossRef]

301. Minchinton, A.I.; Tannock, I.F. Drug penetration in solid tumours. *Nat. Rev. Cancer* 2006, 6, 583–592. [CrossRef] [PubMed]

302. Beyer, I.; van Rensburg, R.; Strauss, R.; Li, Z.; Wang, H.; Persson, J.; Yumul, R.; Feng, Q.; Song, H.; Bartek, J.; et al. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. *Cancer Res.* 2011, 71, 7080–7090. [CrossRef] [PubMed]

303. Yumul, R.; Richter, M.; Lu, Z.Z.; Saydaminova, K.; Wang, H.; Wang, C.H.; Carter, D.; Lieber, A. Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models. *Hum. Gene Ther.* 2016, 27, 325–337. [CrossRef] [PubMed]

304. Wang, C.E.; Yumul, R.C.; Lin, J.; Cheng, Y.; Lieber, A.; Pun, S.H. Junction opener protein increases nanoparticle accumulation in solid tumors. *J. Control. Release* 2018, 272, 9–16. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).